1
|
Bouquet L, Bôle-Richard E, Warda W, Neto Da Rocha M, Trad R, Nicod C, Haderbache R, Genin D, Ferrand C, Deschamps M. RapaCaspase-9-based suicide gene applied to the safety of IL-1RAP CAR-T cells. Gene Ther 2023; 30:706-713. [PMID: 37173386 PMCID: PMC10506905 DOI: 10.1038/s41434-023-00404-2] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/07/2022] [Revised: 03/30/2023] [Accepted: 04/18/2023] [Indexed: 05/15/2023]
Abstract
Even if adoptive cell transfer (ACT) has already shown great clinical efficiency in different types of disease, such as cancer, some adverse events consistently occur, and suicide genes are an interesting system to manage these events. Our team developed a new medical drug candidate, a chimeric antigen receptor (CAR) targeting interleukin-1 receptor accessory protein (IL-1RAP), which needs to be evaluated in clinical trials with a clinically applicable suicide gene system. To prevent side effects and ensure the safety of our candidate, we devised two constructs carrying an inducible suicide gene, RapaCasp9-G or RapaCasp9-A, containing a single-nucleotide polymorphism (rs1052576) affecting the efficiency of endogenous caspase 9. These suicide genes are activated by rapamycin and based on the fusion of human caspase 9 with a modified human FK-binding protein, allowing conditional dimerization. RapaCasp9-G- and RapaCasp9-A-expressing gene-modified T cells (GMTCs) were produced from healthy donors (HDs) and acute myeloid leukemia (AML) donors. The RapaCasp9-G suicide gene demonstrated better efficiency, and we showed its in vitro functionality in different clinically relevant culture conditions. Moreover, as rapamycin is not pharmacologically inert, we also demonstrated its safe use as part of our therapy.
Collapse
Affiliation(s)
- Lucie Bouquet
- Univ. Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, RIGHT Interactions Greffon-Hôte-Tumeur/Ingénierie Cellulaire et Génique, F-25 000, Besançon, France
| | - Elodie Bôle-Richard
- Univ. Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, RIGHT Interactions Greffon-Hôte-Tumeur/Ingénierie Cellulaire et Génique, F-25 000, Besançon, France
| | - Walid Warda
- CanCell Therapeutics, 25 000, Besançon, France
| | | | - Rim Trad
- Univ. Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, RIGHT Interactions Greffon-Hôte-Tumeur/Ingénierie Cellulaire et Génique, F-25 000, Besançon, France
| | - Clémentine Nicod
- Univ. Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, RIGHT Interactions Greffon-Hôte-Tumeur/Ingénierie Cellulaire et Génique, F-25 000, Besançon, France
| | - Rafik Haderbache
- Univ. Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, RIGHT Interactions Greffon-Hôte-Tumeur/Ingénierie Cellulaire et Génique, F-25 000, Besançon, France
| | - Delphine Genin
- Univ. Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, RIGHT Interactions Greffon-Hôte-Tumeur/Ingénierie Cellulaire et Génique, F-25 000, Besançon, France
| | - Christophe Ferrand
- Univ. Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, RIGHT Interactions Greffon-Hôte-Tumeur/Ingénierie Cellulaire et Génique, F-25 000, Besançon, France
- CanCell Therapeutics, 25 000, Besançon, France
| | - Marina Deschamps
- Univ. Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, RIGHT Interactions Greffon-Hôte-Tumeur/Ingénierie Cellulaire et Génique, F-25 000, Besançon, France.
- CanCell Therapeutics, 25 000, Besançon, France.
| |
Collapse
|
2
|
Nicod C, da Rocha MN, Warda W, Roussel X, Haderbache R, Seffar E, Trad R, Bouquet L, Goncalves M, Bosdure L, Laude MC, Guiot M, Ferrand C, Deschamps M. CAR-T cells targeting IL-1RAP produced in a closed semiautomatic system are ready for the first phase I clinical investigation in humans. Curr Res Transl Med 2023; 71:103385. [PMID: 36773434 DOI: 10.1016/j.retram.2023.103385] [Citation(s) in RCA: 5] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/18/2022] [Revised: 01/27/2023] [Accepted: 02/02/2023] [Indexed: 02/05/2023]
Abstract
PURPOSE OF THE STUDY The use of chimeric antigen receptor (CAR)-T cells has demonstrated excellent results in B-lymphoid malignancies. The Advanced Therapy Medicinal Products (ATMP) status and good manufacturing practice (GMP) of CAR-T cells require particular conditions of production performed in a pharmaceutical establishment. Our team developed a new medical drug candidate for acute myeloid leukemia (AML), a CAR targeting interleukin-1 receptor accessory protein (IL-1RAP) expressed by leukemia stem cells, which will need to be evaluated in a phase I-IIa clinical trial. During the preclinical development phase, we produced IL-1RAP CAR-T cells in a semi-automated closed system (CliniMACSࣨ Prodigy) using research grade lentiviral particles. PATIENTS AND THE METHODS The purpose of this work was to validate our production process and to characterize our preclinical GMP-like medicinal product. IL-1RAP CAR-T cells were produced from healthy donors in 9 days, either in an semi-automated closed system (with GMP-like compliant conditions) or according to another research protocols, which was used as a reference. RESULTS Based on phenotypic, functional and metabolic analyses, we were able to show that the final product is ready for clinical use. Finally, in a xenograft AML murine model, we demonstrated that the IL-1RAP CAR-T cells generated in a GMP-like environment could eliminate tumor cells and increase overall survival. CONCLUSION We demonstrated that our IL-1RAP CAR-T cell preclinical GMP-like production process meets standard regulatory requirements in terms of CAR-T cell number, subpopulation phenotype and cytotoxic functionality. Our CAR-T cell production process was validated and can be used to produce medicinal IL-1RAP CAR-T cells for the first phase I clinical trial.
Collapse
Affiliation(s)
- Clémentine Nicod
- Univ. Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, RIGHT Interactions Greffon-Hôte-Tumeur/Ingénierie Cellulaire et Génique, F-25000 Besançon, France
| | - Mathieu Neto da Rocha
- Univ. Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, RIGHT Interactions Greffon-Hôte-Tumeur/Ingénierie Cellulaire et Génique, F-25000 Besançon, France; CanCell Therapeutics, 25000 Besançon, France
| | - Walid Warda
- Univ. Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, RIGHT Interactions Greffon-Hôte-Tumeur/Ingénierie Cellulaire et Génique, F-25000 Besançon, France; CanCell Therapeutics, 25000 Besançon, France
| | - Xavier Roussel
- Univ. Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, RIGHT Interactions Greffon-Hôte-Tumeur/Ingénierie Cellulaire et Génique, F-25000 Besançon, France; Department of Hematology, CHU Besançon, F-25000 Besançon, France
| | - Rafik Haderbache
- Univ. Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, RIGHT Interactions Greffon-Hôte-Tumeur/Ingénierie Cellulaire et Génique, F-25000 Besançon, France
| | - Evan Seffar
- Univ. Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, RIGHT Interactions Greffon-Hôte-Tumeur/Ingénierie Cellulaire et Génique, F-25000 Besançon, France
| | - Rim Trad
- Univ. Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, RIGHT Interactions Greffon-Hôte-Tumeur/Ingénierie Cellulaire et Génique, F-25000 Besançon, France
| | - Lucie Bouquet
- Univ. Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, RIGHT Interactions Greffon-Hôte-Tumeur/Ingénierie Cellulaire et Génique, F-25000 Besançon, France
| | - Mathieu Goncalves
- Univ. Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, RIGHT Interactions Greffon-Hôte-Tumeur/Ingénierie Cellulaire et Génique, F-25000 Besançon, France; Lymphobank S.A.S.U, F-25000 Besançon, France
| | - Léa Bosdure
- Univ. Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, RIGHT Interactions Greffon-Hôte-Tumeur/Ingénierie Cellulaire et Génique, F-25000 Besançon, France
| | - Marie-Charlotte Laude
- Univ. Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, RIGHT Interactions Greffon-Hôte-Tumeur/Ingénierie Cellulaire et Génique, F-25000 Besançon, France
| | - Mélanie Guiot
- Univ. Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, RIGHT Interactions Greffon-Hôte-Tumeur/Ingénierie Cellulaire et Génique, F-25000 Besançon, France
| | - Christophe Ferrand
- Univ. Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, RIGHT Interactions Greffon-Hôte-Tumeur/Ingénierie Cellulaire et Génique, F-25000 Besançon, France; CanCell Therapeutics, 25000 Besançon, France
| | - Marina Deschamps
- Univ. Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, RIGHT Interactions Greffon-Hôte-Tumeur/Ingénierie Cellulaire et Génique, F-25000 Besançon, France; CanCell Therapeutics, 25000 Besançon, France.
| |
Collapse
|
3
|
Da Rocha MN, Guiot M, Nicod C, Trad R, Bouquet L, Haderbache R, Warda W, Baurand PE, Jouanneau C, Dulieu P, Deschamps M, Ferrand C. Coated recombinant target protein helps explore IL-1RAP CAR T-cell functionality in vitro. Immunol Res 2022; 71:276-282. [PMID: 36456721 PMCID: PMC10060290 DOI: 10.1007/s12026-022-09348-y] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/04/2022] [Accepted: 11/23/2022] [Indexed: 12/04/2022]
|
4
|
Frenay J, Bellaye PS, Oudot A, Helbling A, Petitot C, Ferrand C, Collin B, Dias AMM. IL-1RAP, a Key Therapeutic Target in Cancer. Int J Mol Sci 2022; 23:ijms232314918. [PMID: 36499246 PMCID: PMC9735758 DOI: 10.3390/ijms232314918] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/31/2022] [Revised: 11/17/2022] [Accepted: 11/21/2022] [Indexed: 11/30/2022] Open
Abstract
Cancer is a major cause of death worldwide and especially in high- and upper-middle-income countries. Despite recent progress in cancer therapies, such as chimeric antigen receptor T (CAR-T) cells or antibody-drug conjugate (ADC), new targets expressed by the tumor cells need to be identified in order to selectively drive these innovative therapies to tumors. In this context, IL-1RAP recently showed great potential to become one of these new targets for cancer therapy. IL-1RAP is highly involved in the inflammation process through the interleukins 1, 33, and 36 (IL-1, IL-33, IL-36) signaling pathways. Inflammation is now recognized as a hallmark of carcinogenesis, suggesting that IL-1RAP could play a role in cancer development and progression. Furthermore, IL-1RAP was found overexpressed on tumor cells from several hematological and solid cancers, thus confirming its potential involvement in carcinogenesis. This review will first describe the structure and genetics of IL-1RAP as well as its role in tumor development. Finally, a focus will be made on the therapies based on IL-1RAP targeting, which are now under preclinical or clinical development.
Collapse
Affiliation(s)
- Jame Frenay
- Plateforme d'Imagerie et Radiothérapie Précliniques, Médecine Nucléaire, Centre Georges-François Leclerc, 21000 Dijon, France
| | - Pierre-Simon Bellaye
- Plateforme d'Imagerie et Radiothérapie Précliniques, Médecine Nucléaire, Centre Georges-François Leclerc, 21000 Dijon, France
| | - Alexandra Oudot
- Plateforme d'Imagerie et Radiothérapie Précliniques, Médecine Nucléaire, Centre Georges-François Leclerc, 21000 Dijon, France
| | - Alex Helbling
- Plateforme d'Imagerie et Radiothérapie Précliniques, Médecine Nucléaire, Centre Georges-François Leclerc, 21000 Dijon, France
| | - Camille Petitot
- Plateforme d'Imagerie et Radiothérapie Précliniques, Médecine Nucléaire, Centre Georges-François Leclerc, 21000 Dijon, France
| | - Christophe Ferrand
- INSERM UMR1098, EFS BFC, Université de Bourgogne Franche-Comté, 25000 Besançon, France
- CanCell Therapeutics, 25000 Besançon, France
| | - Bertrand Collin
- Plateforme d'Imagerie et Radiothérapie Précliniques, Médecine Nucléaire, Centre Georges-François Leclerc, 21000 Dijon, France
- Institut de Chimie Moléculaire de l'Université de Bourgogne, UMR CNRS 6302, 21000 Dijon, France
| | - Alexandre M M Dias
- Plateforme d'Imagerie et Radiothérapie Précliniques, Médecine Nucléaire, Centre Georges-François Leclerc, 21000 Dijon, France
| |
Collapse
|
5
|
Trad R, Warda W, Alcazer V, Neto da Rocha M, Berceanu A, Nicod C, Haderbache R, Roussel X, Desbrosses Y, Daguindau E, Renosi F, Roumier C, Bouquet L, Biichle S, Guiot M, Seffar E, Caillot D, Depil S, Robinet E, Salma Y, Deconinck E, Deschamps M, Ferrand C. Chimeric antigen receptor T-cells targeting IL-1RAP: a promising new cellular immunotherapy to treat acute myeloid leukemia. J Immunother Cancer 2022; 10:jitc-2021-004222. [PMID: 35803613 PMCID: PMC9272123 DOI: 10.1136/jitc-2021-004222] [Citation(s) in RCA: 11] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 06/27/2022] [Indexed: 11/29/2022] Open
Abstract
Background Acute myeloid leukemia (AML) remains a very difficult disease to cure due to the persistence of leukemic stem cells (LSCs), which are resistant to different lines of chemotherapy and are the basis of refractory/relapsed (R/R) disease in 80% of patients with AML not receiving allogeneic transplantation. Methods In this study, we showed that the interleukin-1 receptor accessory protein (IL-1RAP) protein is overexpressed on the cell surface of LSCs in all subtypes of AML and confirmed it as an interesting and promising target in AML compared with the most common potential AML targets, since it is not expressed by the normal hematopoietic stem cell. After establishing the proof of concept for the efficacy of chimeric antigen receptor (CAR) T-cells targeting IL-1RAP in chronic myeloid leukemia, we hypothesized that third-generation IL-1RAP CAR T-cells could eliminate AML LSCs, where the medical need is not covered. Results We first demonstrated that IL-1RAP CAR T-cells can be produced from AML T-cells at the time of diagnosis and at relapse. In vitro and in vivo, we showed the effectiveness of IL-1RAP CAR T-cells against AML cell lines expressing different levels of IL-1RAP and the cytotoxicity of autologous IL-1RAP CAR T-cells against primary cells from patients with AML at diagnosis or at relapse. In patient-derived relapsed AML xenograft models, we confirmed that IL-1RAP CAR T-cells are able to circulate in peripheral blood and to migrate in the bone marrow and spleen, are cytotoxic against primary AML cells and increased overall survival. Conclusion In conclusion, our preclinical results suggest that IL-1RAP CAR T-based adoptive therapy could be a promising strategy in AML treatment and it warrants the clinical investigation of this CAR T-cell therapy.
Collapse
Affiliation(s)
- Rim Trad
- TIMC, EFSBFC, INSERM UMR1098 RIGHT,UFC, Besancon, France
| | - Walid Warda
- TIMC, EFSBFC, INSERM UMR1098 RIGHT,UFC, Besancon, France.,CanCell Therapeutics, Besancon, France
| | | | - Mathieu Neto da Rocha
- TIMC, EFSBFC, INSERM UMR1098 RIGHT,UFC, Besancon, France.,CanCell Therapeutics, Besancon, France
| | - Ana Berceanu
- Clinical Hematology, C.H. Univ Jean Minjoz, Besancon, France
| | | | | | - Xavier Roussel
- Clinical Hematology, C.H. Univ Jean Minjoz, Besancon, France
| | | | | | - Florain Renosi
- TIMC, EFSBFC, INSERM UMR1098 RIGHT,UFC, Besancon, France
| | | | - Lucie Bouquet
- TIMC, EFSBFC, INSERM UMR1098 RIGHT,UFC, Besancon, France
| | - Sabeha Biichle
- TIMC, EFSBFC, INSERM UMR1098 RIGHT,UFC, Besancon, France
| | - Melanie Guiot
- TIMC, EFSBFC, INSERM UMR1098 RIGHT,UFC, Besancon, France
| | - Evan Seffar
- TIMC, EFSBFC, INSERM UMR1098 RIGHT,UFC, Besancon, France
| | - Denis Caillot
- Clinical Hematology, CHU François Mitterrand, Dijon, France
| | | | | | - Yahya Salma
- Laboratory of Applied Biotechnology (LBA3B), Lebanese University, Tripoli, Lebanon
| | - Eric Deconinck
- Clinical Hematology, C.H. Univ Jean Minjoz, Besancon, France
| | - Marina Deschamps
- TIMC, EFSBFC, INSERM UMR1098 RIGHT,UFC, Besancon, France.,CanCell Therapeutics, Besancon, France
| | - Christophe Ferrand
- TIMC, EFSBFC, INSERM UMR1098 RIGHT,UFC, Besancon, France .,CanCell Therapeutics, Besancon, France
| |
Collapse
|
6
|
de Nattes T, Camus V, François A, Dallet G, Ferrand C, Guerrot D, Lemoine M, Morin F, Thieblemont C, Veresezan EL, Candon S, Latouche JB, Bertrand D. Kidney Transplant T Cell-Mediated Rejection Occurring After Anti-CD19 CAR T-Cell Therapy for Refractory Aggressive Burkitt-like Lymphoma With 11q Aberration: A Case Report. Am J Kidney Dis 2021; 79:760-764. [PMID: 34461166 DOI: 10.1053/j.ajkd.2021.07.012] [Citation(s) in RCA: 13] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/12/2020] [Accepted: 07/17/2021] [Indexed: 02/06/2023]
Abstract
Post-transplant lymphoproliferative disorder is a growing complication of kidney transplantation and is associated with a poor prognosis. Anti-CD19 chimeric antigen receptor (CAR) T-cell therapy is an important new treatment option modifying the outcome of refractory hematological cancers. Here, we report the case of a 40-year-old kidney transplant recipient who developed a Burkitt-like lymphoma with 11q aberration 5 years after transplantation. After 3 unsuccessful lines of chemotherapy, it was decided to treat the patient with anti-CD19 CAR T cells as a salvage therapy. Three months after CAR T-cell infusion, she experienced a grade IIB T cell-mediated rejection with severe tubulitis (T3), slight interstitial inflammation (I1), and severe intimal arteritis (V2) with blood suffusion. Among T cells infiltrating the graft, some of them expressed the anti-CD19 CAR. CAR T cells within the graft and in blood samples were also detected by droplet digital polymerase chain reaction. Function of the kidney transplant improved after corticosteroid treatment and remained stable. However, lymphoma progressed, with a massive pulmonary mass leading to the patient's death 10 months after CAR T-cell infusion.
Collapse
Affiliation(s)
- Tristan de Nattes
- Nephrology - Kidney Transplant Unit, Rouen University Hospital, Rouen, France; Normandy University, UNIROUEN, INSERM, U1234, Rouen, France.
| | - Vincent Camus
- Department of Hematology, Centre Henri Becquerel, Normandie University, Rouen, France
| | - Arnaud François
- Pathology Department, Rouen University Hospital, Rouen, France
| | - Grégoire Dallet
- Nephrology - Kidney Transplant Unit, Rouen University Hospital, Rouen, France
| | - Christophe Ferrand
- INSERM UMR1098 Right, Etablissement Français du Sang Bourgogne Franche-Comté University Franche-Comté, Besançon, France
| | - Dominique Guerrot
- Nephrology - Kidney Transplant Unit, Rouen University Hospital, Rouen, France
| | - Mathilde Lemoine
- Nephrology - Kidney Transplant Unit, Rouen University Hospital, Rouen, France
| | - Florence Morin
- Laboratoire d'Immunologie-Histocompatibilité, Hôpital Saint Louis, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Catherine Thieblemont
- Hemato-Oncology Department, Saint-Louis Hospital, Diderot University-Sorbonne Paris Cité, Paris, France
| | | | - Sophie Candon
- Normandy University, UNIROUEN, INSERM, U1234, Rouen, France
| | | | - Dominique Bertrand
- Nephrology - Kidney Transplant Unit, Rouen University Hospital, Rouen, France
| |
Collapse
|
7
|
Rubio MT, Varlet P, Allain V, Ballot C, Cuffel A, Deschamps M, Ferrand C, Foguenne J, Forcade E, Huynh A, Guihot A, Latouche JB, Lemarie C, Martinroche G, Morin F, Nguyen S, Schmit K, Servais S, Simonetta F, Yakoub-Agha I, Caillat Zucman S. [Immunomonitoring of patients treated with CAR-T cells for hematological malignancy: Guidelines from the CARTi group and the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)]. Bull Cancer 2021; 108:S53-S64. [PMID: 34253335 DOI: 10.1016/j.bulcan.2021.04.008] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/25/2021] [Revised: 03/24/2021] [Accepted: 04/09/2021] [Indexed: 12/25/2022]
Abstract
CAR-T cells represent a new anti-tumor immunotherapy which has shown its clinical efficacy in B-cell malignancies. The results of clinical trials carried out in this context have shown that certain immunological characteristics of patients before (at the time of apheresis) and after the administration of the treatment, or of the CAR-T cells themselves, are correlated with the response to the treatment or to its toxicity. However, to date, there are no recommendations on the immunological monitoring of patients treated in real life. The objectives of this workshop were to determine, based on data from the literature and the experience of the centers, the immunological analyses to be carried out in patients treated with CAR-T cells. The recommendations relate to the characterization of the patient's immune cells at the time of apheresis, the characterization of the injected CAR-T cells, as well as the monitoring of the CAR-T cells and other parameters of immune reconstitution in the patient after administration of the treatment. Harmonization of practices will allow clinical-biological correlation studies to be carried out in patients treated in real life with the aim of identifying factors predictive of response and toxicity. Such data could have a major medico-economic impact by making it possible to identify the patients who will optimally benefit from these expensive treatments.
Collapse
Affiliation(s)
- Marie Thérèse Rubio
- CHRU Nancy, Hopital Brabois, Biopole de l'Université de Lorraine, CNRS UMR 7563 IMoPa, Service d'hématologie, 54500 Vandoeuvre-les-Nancy, France.
| | - Pauline Varlet
- Université de Lille, CHU de Lille, Laboratoire d'Immunologie, LIRIC, INSERM U995, 59000 Lille, France
| | - Vincent Allain
- Université de Paris, Hôpital Saint-Louis, AP-HP Nord, Laboratoire d'Immunologie, France
| | - Caroline Ballot
- Établissement Français du Sang Hauts-de-France, Unité de Thérapie Cellulaire EFS site de Lille, Normandie, France
| | - Alexis Cuffel
- Université de Paris, Hôpital Saint-Louis, AP-HP Nord, Laboratoire d'Immunologie, France
| | - Marina Deschamps
- Ets Bourgogne Franche-Comté, INSERM UMR1098, 25020 Besançon, France
| | | | - Jacques Foguenne
- CHU de Liège, domaine universitaire du Sart-Tilman B35, Laboratoire d'Hématologie Biologique, Unilab Lg, 4000 Liège, Belgique
| | - Edouard Forcade
- CHU Bordeaux, service d'hématologie clinique et thérapie cellulaire, 33000 Bordeaux, France
| | - Anne Huynh
- IUCT Oncopole, service d'hématologie, Toulouse, France
| | - Amélie Guihot
- Hôpital Pitié-Salpêtrière, AP-HP, département d'immunologie, 75013, Paris, France
| | - Jean-Baptiste Latouche
- CHU de Rouen, UMR Université/Inserm U1234, Laboratoire d'Immunologie et Biothérapies, France
| | - Claude Lemarie
- Institut Paoli-Calmettes, and Inserm CBT 1409, Centre d'Investigations Cliniques en Biothérapie, Marseille, France
| | - Guillaume Martinroche
- Centre Hospitalier Universitaire de Bordeaux, Laboratoire d'Immunologie et Immunogénétique, place Amélie Raba Léon, 33076 Bordeaux, France
| | - Florence Morin
- Université de Paris, Hôpital Saint-Louis, AP-HP Nord, Laboratoire d'Immunologie, France
| | - Stéphanie Nguyen
- Hôpital Pitié-Salpêtrière, AP-HP, service d'hématologie 75013, Paris, France
| | - Kathleen Schmit
- CHU de Liège, domaine universitaire du Sart-Tilman B35, Laboratoire d'Hématologie Biologique, Unilab Lg, 4000 Liège, Belgique
| | - Sophie Servais
- Université de Liège, CHU de Liège, service d'hématologie, 4000 Liège, Belgique
| | - Federico Simonetta
- University of Geneva, Division of Hematology, Department of Oncology, Geneva University Hospitals and Faculty of Medicine and Translational Research Center for Oncohematology, Department of Internal Medicine Specialties, Geneva, Suisse
| | | | - Sophie Caillat Zucman
- Université de Paris, Hôpital Saint-Louis, AP-HP Nord, Laboratoire d'Immunologie, France
| |
Collapse
|
8
|
Haderbache R, Warda W, Hervouet E, da Rocha MN, Trad R, Allain V, Nicod C, Thieblemeont C, Boissel N, Varlet P, Agha IY, Bouquet L, Guiot M, Venet F, Sujobert P, Roussel X, Rouzaire PO, Caillot D, Casasnovas O, Bories JC, Bachy E, Caillat-Zucman S, Deschamps M, Ferrand C. Droplet digital PCR allows vector copy number assessment and monitoring of experimental CAR T cells in murine xenograft models or approved CD19 CAR T cell-treated patients. J Transl Med 2021; 19:265. [PMID: 34154602 PMCID: PMC8215786 DOI: 10.1186/s12967-021-02925-z] [Citation(s) in RCA: 16] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/25/2021] [Accepted: 06/03/2021] [Indexed: 01/04/2023] Open
Abstract
BACKGROUND Genetically engineered chimeric antigen receptor (CAR) T lymphocytes are promising therapeutic tools for cancer. Four CAR T cell drugs, including tisagenlecleucel (tisa-cel) and axicabtagene-ciloleucel (axi-cel), all targeting CD19, are currently approved for treating B cell malignancies. Flow cytometry (FC) remains the standard for monitoring CAR T cells using a recombinant biotinylated target protein. Nevertheless, there is a need for additional tools, and the challenge is to develop an easy, relevant, highly sensitive, reproducible, and inexpensive detection method. Molecular tools can meet this need to specifically monitor long-term persistent CAR T cells. METHODS Based on 2 experimental CAR T cell constructs, IL-1RAP and CS1, we designed 2 quantitative digital droplet (ddPCR) PCR assays. By targeting the 4.1BB/CD3z (28BBz) or 28/CD3z (28z) junction area, we demonstrated that PCR assays can be applied to approved CD19 CAR T drugs. Both 28z and 28BBz ddPCR assays allow determination of the average vector copy number (VCN) per cell. We confirmed that the VCN is dependent on the multiplicity of infection and verified that the VCN of our experimental or GMP-like IL-1RAP CAR T cells met the requirement (< 5 VCN/cell) for delivery to the clinical department, similar to approved axi-cel or tisa-cel drugs. RESULTS 28BBz and 28z ddPCR assays applied to 2 tumoral (acute myeloid leukemia (AML) or multiple myeloma (MM) xenograft humanized NSG mouse models allowed us to quantify the early expansion (up to day 30) of CAR T cells after injection. Interestingly, following initial expansion, when circulating CAR T cells were challenged with the tumor, we noted a second expansion phase. Investigation of the bone marrow, spleen and lung showed that CAR T cells disseminated more within these tissues in mice previously injected with leukemic cell lines. Finally, circulating CAR T cell ddPCR monitoring of R/R acute lymphoid leukemia or diffuse large B cell lymphoma (n = 10 for tisa-cel and n = 7 for axi-cel) patients treated with both approved CAR T cells allowed detection of early expansion, which was highly correlated with FC, as well as long-term persistence (up to 450 days), while FC failed to detect these events. CONCLUSION Overall, we designed and validated 2 ddPCR assays allowing routine or preclinical monitoring of early- and long-term circulating approved or experimental CAR T cells, including our own IL-1RAP CAR T cells, which will be evaluated in an upcoming phase I clinical trial.
Collapse
Affiliation(s)
- Rafik Haderbache
- INSERM UMR1098, Right, EFSBFC, UFC, Laboratoire de Thérapeutique Immuno-Moléculaire Et Cellulaire Des Cancers, 8 rue du Dr Jean François Xavier Girod, 25020, Besançon, France
| | - Walid Warda
- INSERM UMR1098, Right, EFSBFC, UFC, Laboratoire de Thérapeutique Immuno-Moléculaire Et Cellulaire Des Cancers, 8 rue du Dr Jean François Xavier Girod, 25020, Besançon, France
| | - Eric Hervouet
- INSERM UMR1098, Right, EFSBFC, UFC, Laboratoire de Thérapeutique Immuno-Moléculaire Et Cellulaire Des Cancers, 8 rue du Dr Jean François Xavier Girod, 25020, Besançon, France
| | - Mathieu Neto da Rocha
- INSERM UMR1098, Right, EFSBFC, UFC, Laboratoire de Thérapeutique Immuno-Moléculaire Et Cellulaire Des Cancers, 8 rue du Dr Jean François Xavier Girod, 25020, Besançon, France
| | - Rim Trad
- INSERM UMR1098, Right, EFSBFC, UFC, Laboratoire de Thérapeutique Immuno-Moléculaire Et Cellulaire Des Cancers, 8 rue du Dr Jean François Xavier Girod, 25020, Besançon, France
| | - Vincent Allain
- Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris (AP-HP), Université de Paris, Service d'Immunologie, Paris, France
| | - Clementine Nicod
- INSERM UMR1098, Right, EFSBFC, UFC, Laboratoire de Thérapeutique Immuno-Moléculaire Et Cellulaire Des Cancers, 8 rue du Dr Jean François Xavier Girod, 25020, Besançon, France
| | - Catherine Thieblemeont
- Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris (AP-HP), Université de Paris, Service Hématologie, Paris, France
| | - Nicolas Boissel
- Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris (AP-HP), Université de Paris, Service Hématologie, Paris, France
| | | | | | - Lucie Bouquet
- INSERM UMR1098, Right, EFSBFC, UFC, Laboratoire de Thérapeutique Immuno-Moléculaire Et Cellulaire Des Cancers, 8 rue du Dr Jean François Xavier Girod, 25020, Besançon, France
| | - Melanie Guiot
- INSERM UMR1098, Right, EFSBFC, UFC, Laboratoire de Thérapeutique Immuno-Moléculaire Et Cellulaire Des Cancers, 8 rue du Dr Jean François Xavier Girod, 25020, Besançon, France
| | - Fabienne Venet
- Hospices Civils de Lyon, Immunology Laboratory, Edouard Herriot Hospital, Lyon, France
| | - Pierre Sujobert
- Hospices Civils de Lyon, Hôpital Lyon Sud, Service d'Hématologie Biologique, Lyon, France
| | - Xavier Roussel
- INSERM UMR1098, Right, EFSBFC, UFC, Laboratoire de Thérapeutique Immuno-Moléculaire Et Cellulaire Des Cancers, 8 rue du Dr Jean François Xavier Girod, 25020, Besançon, France
| | - Paul-Oliver Rouzaire
- UFR de Pharmacie, EA CHELTER 7453, CHU de Clermont-Ferrand, Clermont-Ferrand, France
| | - Denis Caillot
- Hematology Clinical Department, Mitterrand Hospital, Dijon, France
| | | | | | - Emmanuel Bachy
- Hospices Civils de Lyon, Hospital Lyon Sud, Service d'Hématologie Clinique, Lyon, France
| | - Sophie Caillat-Zucman
- Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris (AP-HP), Université de Paris, Service d'Immunologie, Paris, France
| | - Marina Deschamps
- INSERM UMR1098, Right, EFSBFC, UFC, Laboratoire de Thérapeutique Immuno-Moléculaire Et Cellulaire Des Cancers, 8 rue du Dr Jean François Xavier Girod, 25020, Besançon, France
| | - Christophe Ferrand
- INSERM UMR1098, Right, EFSBFC, UFC, Laboratoire de Thérapeutique Immuno-Moléculaire Et Cellulaire Des Cancers, 8 rue du Dr Jean François Xavier Girod, 25020, Besançon, France.
| |
Collapse
|
9
|
Warda W, Da Rocha MN, Trad R, Haderbache R, Salma Y, Bouquet L, Roussel X, Nicod C, Deschamps M, Ferrand C. Overcoming target epitope masking resistance that can occur on low-antigen-expresser AML blasts after IL-1RAP chimeric antigen receptor T cell therapy using the inducible caspase 9 suicide gene safety switch. Cancer Gene Ther 2021; 28:1365-1375. [PMID: 33414517 PMCID: PMC8636256 DOI: 10.1038/s41417-020-00284-3] [Citation(s) in RCA: 17] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/06/2020] [Revised: 11/27/2020] [Accepted: 12/04/2020] [Indexed: 12/31/2022]
Abstract
Although chimeric antigen receptor CAR) T cell immunotherapies are an undeniable and unequivocal success, knowledge obtained from the monitoring of the first clinical trials targeting the CD19 antigen in B malignancies, either refractory/relapsed acute lymphoid leukemia (ALL) or lymphomas, contributed to the identification of tumor cell escape in about 30–50% of B-ALL. Resistance occurred due to loss of surface expression of the antigen (rCD19−) or to the early disappearance or inactivation of CAR T cells (rCD19+). In a recently reported clinical case, rCD19− relapse resulted from masking of the antigen by the CAR at the surface of B-ALL leukemia cells following the unexpected viral transduction of a leukemic cell present in the cytapheresis sample. The objective of this work was to reproduce this epitope-masking resistance model, in the context of acute myeloid leukemia (AML), based on our immunotherapeutic CAR T cell model targeting the accessory protein of the interleukin-1 receptor (IL-1RAP) expressed by leukemic stem cells. As AML primary blasts express different levels of IL-1RAP, we modeled transduction of different AML tumor cell lines screened for density of antigenic sites with our lentiviral vectors carrying a third-generation IL-1RAP CAR, an iCASP9 suicide gene, and a truncated CD19 surface gene. We demonstrated that primary AML blasts can be easily transduced (74.55 ± 21.29%, n = 4) and that CAR T cytotoxicity to IL-1RAP is inversely correlated with epitope masking in relation to the number of antigenic sites expressed on the surface of IL-1RAP+ lines. Importantly, we showed that, in vitro, a 24-h exposure of IL-1RAP+/CAR+ leukemia lines to Rimiducid eliminated >85% of the cells. We confirmed that the expression of IL-1RAP CAR by an IL-1RAP+ leukemic cell, by decreasing the membrane availability of the targeted antigen, can induce resistance while a high epitope density maintains sensitivity to CAR T cells. Moreover, the presence of the iCASP9/Rimiducid suicide system safety switch makes this immunotherapy approach safe for application in a future phase 1 clinical trial.
Collapse
Affiliation(s)
- Walid Warda
- INSERM UMR1098 Right, EFS BFC, Univ. Bourgogne Franche-Comté, 25000, Besançon, France
| | - Mathieu Neto Da Rocha
- INSERM UMR1098 Right, EFS BFC, Univ. Bourgogne Franche-Comté, 25000, Besançon, France
| | - Rim Trad
- INSERM UMR1098 Right, EFS BFC, Univ. Bourgogne Franche-Comté, 25000, Besançon, France
| | - Rafik Haderbache
- INSERM UMR1098 Right, EFS BFC, Univ. Bourgogne Franche-Comté, 25000, Besançon, France
| | - Yahya Salma
- Laboratory of Applied Biotechnology (LBA3B), AZM Center for Research in Biotechnology and its Applications, Lebanese University, Tripoli, 1300, Lebanon
| | - Lucie Bouquet
- INSERM UMR1098 Right, EFS BFC, Univ. Bourgogne Franche-Comté, 25000, Besançon, France
| | - Xavier Roussel
- INSERM UMR1098 Right, EFS BFC, Univ. Bourgogne Franche-Comté, 25000, Besançon, France.,Hematology Department, Hôpital Jean Minjoz, 25000, Besançon, France
| | - Clémentine Nicod
- INSERM UMR1098 Right, EFS BFC, Univ. Bourgogne Franche-Comté, 25000, Besançon, France
| | - Marina Deschamps
- INSERM UMR1098 Right, EFS BFC, Univ. Bourgogne Franche-Comté, 25000, Besançon, France
| | - Christophe Ferrand
- INSERM UMR1098 Right, EFS BFC, Univ. Bourgogne Franche-Comté, 25000, Besançon, France.
| |
Collapse
|
10
|
Roussel X, Daguindau E, Berceanu A, Desbrosses Y, Warda W, Neto da Rocha M, Trad R, Deconinck E, Deschamps M, Ferrand C. Acute Myeloid Leukemia: From Biology to Clinical Practices Through Development and Pre-Clinical Therapeutics. Front Oncol 2020; 10:599933. [PMID: 33363031 PMCID: PMC7757414 DOI: 10.3389/fonc.2020.599933] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/28/2020] [Accepted: 11/02/2020] [Indexed: 12/19/2022] Open
Abstract
Recent studies have provided several insights into acute myeloid leukemia. Studies based on molecular biology have identified eight functional mutations involved in leukemogenesis, including driver and passenger mutations. Insight into Leukemia stem cells (LSCs) and assessment of cell surface markers have enabled characterization of LSCs from hematopoietic stem and progenitor cells. Clonal evolution has been described as having an effect similar to that of microenvironment alterations. Such biological findings have enabled the development of new targeted drugs, including drug inhibitors and monoclonal antibodies with blockage functions. Some recently approved targeted drugs have resulted in new therapeutic strategies that enhance standard intensive chemotherapy regimens as well as supportive care regimens. Besides the progress made in adoptive immunotherapy, since allogenic hematopoietic stem cell transplantation enabled the development of new T-cell transfer therapies, such as chimeric antigen receptor T-cell and transgenic TCR T-cell engineering, new promising strategies that are investigated.
Collapse
Affiliation(s)
- Xavier Roussel
- Inserm EFS BFC, UMR1098 RIGHT, University Bourgogne Franche-Comté, Besançon, France
- Department of Hematology, University Hospital of Besançon, Besançon, France
| | - Etienne Daguindau
- Inserm EFS BFC, UMR1098 RIGHT, University Bourgogne Franche-Comté, Besançon, France
- Department of Hematology, University Hospital of Besançon, Besançon, France
| | - Ana Berceanu
- Department of Hematology, University Hospital of Besançon, Besançon, France
| | - Yohan Desbrosses
- Department of Hematology, University Hospital of Besançon, Besançon, France
| | - Walid Warda
- Inserm EFS BFC, UMR1098 RIGHT, University Bourgogne Franche-Comté, Besançon, France
| | | | - Rim Trad
- Inserm EFS BFC, UMR1098 RIGHT, University Bourgogne Franche-Comté, Besançon, France
| | - Eric Deconinck
- Inserm EFS BFC, UMR1098 RIGHT, University Bourgogne Franche-Comté, Besançon, France
- Department of Hematology, University Hospital of Besançon, Besançon, France
| | - Marina Deschamps
- Inserm EFS BFC, UMR1098 RIGHT, University Bourgogne Franche-Comté, Besançon, France
| | - Christophe Ferrand
- Inserm EFS BFC, UMR1098 RIGHT, University Bourgogne Franche-Comté, Besançon, France
| |
Collapse
|
11
|
Lachat C, Bruyère D, Etcheverry A, Aubry M, Mosser J, Warda W, Herfs M, Hendrick E, Ferrand C, Borg C, Delage-Mourroux R, Feugeas JP, Guittaut M, Hervouet E, Peixoto P. EZH2 and KDM6B Expressions Are Associated with Specific Epigenetic Signatures during EMT in Non Small Cell Lung Carcinomas. Cancers (Basel) 2020; 12:E3649. [PMID: 33291363 PMCID: PMC7762040 DOI: 10.3390/cancers12123649] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/28/2020] [Revised: 11/26/2020] [Accepted: 11/28/2020] [Indexed: 01/18/2023] Open
Abstract
The role of Epigenetics in Epithelial Mesenchymal Transition (EMT) has recently emerged. Two epigenetic enzymes with paradoxical roles have previously been associated to EMT, EZH2 (Enhancer of Zeste 2 Polycomb Repressive Complex 2 (PRC2) Subunit), a lysine methyltranserase able to add the H3K27me3 mark, and the histone demethylase KDM6B (Lysine Demethylase 6B), which can remove the H3K27me3 mark. Nevertheless, it still remains unclear how these enzymes, with apparent opposite activities, could both promote EMT. In this study, we evaluated the function of these two enzymes using an EMT-inducible model, the lung cancer A549 cell line. ChIP-seq coupled with transcriptomic analysis showed that EZH2 and KDM6B were able to target and modulate the expression of different genes during EMT. Based on this analysis, we described INHBB, WTN5B, and ADAMTS6 as new EMT markers regulated by epigenetic modifications and directly implicated in EMT induction.
Collapse
Affiliation(s)
- Camille Lachat
- UMR1098, RIGHT, Université Bourgogne Franche-Comté, INSERM, EFS BFC, F-25000 Besançon, France; (C.L.); (W.W.); (C.F.); (C.B.); (R.D.-M.); (J.-P.F.); (M.G.)
| | - Diane Bruyère
- Laboratory of Experimental Pathology, GIGA-Cancer, University of Liege, 4000 Liege, Belgium; (D.B.); (M.H.); (E.H.)
| | - Amandine Etcheverry
- Service de Génétique Moléculaire et Génomique, CHU Rennes, F-35033 Rennes, France; (A.E.); (M.A.); (J.M.)
- Plate-Forme Génomique Environnementale et Humaine Biosit, Université Rennes1, F-35043 Rennes, France
- UMR 6290, CNRS, Institut de Génétique et Développement de Rennes (IGDR), F-35043 Rennes, France
- UMS 3480 Biosit, Faculté de Médecine, Université Rennes1, UEB, F-35043 Rennes, France
| | - Marc Aubry
- Service de Génétique Moléculaire et Génomique, CHU Rennes, F-35033 Rennes, France; (A.E.); (M.A.); (J.M.)
- Plate-Forme Génomique Environnementale et Humaine Biosit, Université Rennes1, F-35043 Rennes, France
- UMR 6290, CNRS, Institut de Génétique et Développement de Rennes (IGDR), F-35043 Rennes, France
- UMS 3480 Biosit, Faculté de Médecine, Université Rennes1, UEB, F-35043 Rennes, France
| | - Jean Mosser
- Service de Génétique Moléculaire et Génomique, CHU Rennes, F-35033 Rennes, France; (A.E.); (M.A.); (J.M.)
- Plate-Forme Génomique Environnementale et Humaine Biosit, Université Rennes1, F-35043 Rennes, France
- UMR 6290, CNRS, Institut de Génétique et Développement de Rennes (IGDR), F-35043 Rennes, France
- UMS 3480 Biosit, Faculté de Médecine, Université Rennes1, UEB, F-35043 Rennes, France
| | - Walid Warda
- UMR1098, RIGHT, Université Bourgogne Franche-Comté, INSERM, EFS BFC, F-25000 Besançon, France; (C.L.); (W.W.); (C.F.); (C.B.); (R.D.-M.); (J.-P.F.); (M.G.)
| | - Michaël Herfs
- Laboratory of Experimental Pathology, GIGA-Cancer, University of Liege, 4000 Liege, Belgium; (D.B.); (M.H.); (E.H.)
| | - Elodie Hendrick
- Laboratory of Experimental Pathology, GIGA-Cancer, University of Liege, 4000 Liege, Belgium; (D.B.); (M.H.); (E.H.)
| | - Christophe Ferrand
- UMR1098, RIGHT, Université Bourgogne Franche-Comté, INSERM, EFS BFC, F-25000 Besançon, France; (C.L.); (W.W.); (C.F.); (C.B.); (R.D.-M.); (J.-P.F.); (M.G.)
| | - Christophe Borg
- UMR1098, RIGHT, Université Bourgogne Franche-Comté, INSERM, EFS BFC, F-25000 Besançon, France; (C.L.); (W.W.); (C.F.); (C.B.); (R.D.-M.); (J.-P.F.); (M.G.)
| | - Régis Delage-Mourroux
- UMR1098, RIGHT, Université Bourgogne Franche-Comté, INSERM, EFS BFC, F-25000 Besançon, France; (C.L.); (W.W.); (C.F.); (C.B.); (R.D.-M.); (J.-P.F.); (M.G.)
| | - Jean-Paul Feugeas
- UMR1098, RIGHT, Université Bourgogne Franche-Comté, INSERM, EFS BFC, F-25000 Besançon, France; (C.L.); (W.W.); (C.F.); (C.B.); (R.D.-M.); (J.-P.F.); (M.G.)
| | - Michaël Guittaut
- UMR1098, RIGHT, Université Bourgogne Franche-Comté, INSERM, EFS BFC, F-25000 Besançon, France; (C.L.); (W.W.); (C.F.); (C.B.); (R.D.-M.); (J.-P.F.); (M.G.)
- DImaCell Platform, Université Bourgogne Franche-Comté, F-25000 Besançon, France
| | - Eric Hervouet
- UMR1098, RIGHT, Université Bourgogne Franche-Comté, INSERM, EFS BFC, F-25000 Besançon, France; (C.L.); (W.W.); (C.F.); (C.B.); (R.D.-M.); (J.-P.F.); (M.G.)
- DImaCell Platform, Université Bourgogne Franche-Comté, F-25000 Besançon, France
- EPIGENExp (EPIgenetics and GENe EXPression Technical Platform), Université Bourgogne Franche-Comté, F-25000 Besançon, France
| | - Paul Peixoto
- UMR1098, RIGHT, Université Bourgogne Franche-Comté, INSERM, EFS BFC, F-25000 Besançon, France; (C.L.); (W.W.); (C.F.); (C.B.); (R.D.-M.); (J.-P.F.); (M.G.)
- EPIGENExp (EPIgenetics and GENe EXPression Technical Platform), Université Bourgogne Franche-Comté, F-25000 Besançon, France
| |
Collapse
|
12
|
Crépin T, Legendre M, Carron C, Vachey C, Courivaud C, Rebibou JM, Ferrand C, Laheurte C, Vauchy C, Gaiffe E, Saas P, Ducloux D, Bamoulid J. Uraemia-induced immune senescence and clinical outcomes in chronic kidney disease patients. Nephrol Dial Transplant 2020; 35:624-632. [PMID: 30202981 DOI: 10.1093/ndt/gfy276] [Citation(s) in RCA: 54] [Impact Index Per Article: 13.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/09/2018] [Accepted: 07/09/2018] [Indexed: 12/11/2022] Open
Abstract
BACKGROUND Patients with chronic kidney disease (CKD) are more prone to develop premature age-related diseases. Data on immune senescence are scarce in CKD populations, except in end-stage renal disease and dialysis. We designed a longitudinal prospective study to evaluate immune senescence at different CKD stages and its influence on CKD patient outcomes. METHODS Clinical and biological data collections were performed on 222 patients at different CKD stages [1-2 (n = 85), 4 (n = 53) and 5 (n = 84)]. Immune senescence biomarkers were measured by cytometry on T cells (CD28, CD57, CD45RA, CD31, γH2A.X) or by quantitative polymerase chain reaction [relative telomere length (RTL)] on peripheral blood mononuclear cells and analysed according to CKD stages and outcomes. RESULTS CKD was associated with an increase in immune senescence and inflammation biomarkers, as follows: low thymic output (197 ± 25 versus 88 ± 13 versus 73 ± 21 CD4+CD45RA+CD31+ T cells/mm3), an increased proportion of terminally differentiated T cells (CD8+CD28-CD57+) (24 ± 18 versus 32 ± 17 versus 35 ± 19%) restricted to cytomegalovirus-positive patients, telomere shortening (1.11 ± 0.36 versus 0.78 ± 0.24 versus 0.97 ± 0.21 telomere:single copy ratio) and an increase in C-reactive protein levels [median 2.9 (range 1.8-4.9) versus 5.1 (27-9.6) versus 6.2 (3.4-10.5) mg/L]. In multivariate analysis, shorter RTL was associated with death {hazard ratio [HR] 4.12 [95% confidence interval (CI) 1.44-11.75]}. Low thymic output was associated with infections [HR 1.79 (95% CI (1.34-9.58)] and terminally differentiated CD8+ T-cell expansion with a risk of cardiovascular events [CEs; HR 4.86 (95% CI 1.72-13.72)]. CONCLUSION CKD was associated with premature immune ageing. Each of these alterations increased the risk of specific age-related diseases, such as RTL and death, thymic function and infections and terminally differentiated CD8+ T-cell expansion and CEs.
Collapse
Affiliation(s)
- Thomas Crépin
- INSERM, UMR1098, Federation Hospitalo-Universitaire, INCREASE, Besançon, France.,University of Bourgogne-Franche-Comté, Faculté de Médecine et de Pharmacie, LabEx LipSTIC, Besançon and Dijon, France.,CHU Besançon, Department of Nephrology, Dialysis, and Renal Transplantation, Besançon, France
| | - Mathieu Legendre
- INSERM, UMR1098, Federation Hospitalo-Universitaire, INCREASE, Besançon, France.,University of Bourgogne-Franche-Comté, Faculté de Médecine et de Pharmacie, LabEx LipSTIC, Besançon and Dijon, France
| | - Clémence Carron
- INSERM, UMR1098, Federation Hospitalo-Universitaire, INCREASE, Besançon, France
| | - Clément Vachey
- CHU Besançon, Department of Nephrology, Dialysis, and Renal Transplantation, Besançon, France.,CHU Besançon, CIC Biothérapie, INSERM CIC-1431, Besançon, France
| | - Cécile Courivaud
- INSERM, UMR1098, Federation Hospitalo-Universitaire, INCREASE, Besançon, France.,University of Bourgogne-Franche-Comté, Faculté de Médecine et de Pharmacie, LabEx LipSTIC, Besançon and Dijon, France.,CHU Besançon, Department of Nephrology, Dialysis, and Renal Transplantation, Besançon, France
| | - Jean-Michel Rebibou
- INSERM, UMR1098, Federation Hospitalo-Universitaire, INCREASE, Besançon, France.,University of Bourgogne-Franche-Comté, Faculté de Médecine et de Pharmacie, LabEx LipSTIC, Besançon and Dijon, France
| | - Christophe Ferrand
- INSERM, UMR1098, Federation Hospitalo-Universitaire, INCREASE, Besançon, France.,University of Bourgogne-Franche-Comté, Faculté de Médecine et de Pharmacie, LabEx LipSTIC, Besançon and Dijon, France.,EFS Bourgogne Franche-Comté, Plateforme de Biomonitoring, INSERM CIC-1431/UMR1098, Besançon, France
| | - Caroline Laheurte
- INSERM, UMR1098, Federation Hospitalo-Universitaire, INCREASE, Besançon, France.,EFS Bourgogne Franche-Comté, Plateforme de Biomonitoring, INSERM CIC-1431/UMR1098, Besançon, France
| | - Charline Vauchy
- CHU Besançon, CIC Biothérapie, INSERM CIC-1431, Besançon, France
| | - Emilie Gaiffe
- CHU Besançon, CIC Biothérapie, INSERM CIC-1431, Besançon, France
| | - Philippe Saas
- INSERM, UMR1098, Federation Hospitalo-Universitaire, INCREASE, Besançon, France.,University of Bourgogne-Franche-Comté, Faculté de Médecine et de Pharmacie, LabEx LipSTIC, Besançon and Dijon, France.,CHU Besançon, CIC Biothérapie, INSERM CIC-1431, Besançon, France.,EFS Bourgogne Franche-Comté, Plateforme de Biomonitoring, INSERM CIC-1431/UMR1098, Besançon, France
| | - Didier Ducloux
- INSERM, UMR1098, Federation Hospitalo-Universitaire, INCREASE, Besançon, France.,University of Bourgogne-Franche-Comté, Faculté de Médecine et de Pharmacie, LabEx LipSTIC, Besançon and Dijon, France.,CHU Besançon, Department of Nephrology, Dialysis, and Renal Transplantation, Besançon, France.,CHU Besançon, CIC Biothérapie, INSERM CIC-1431, Besançon, France
| | - Jamal Bamoulid
- INSERM, UMR1098, Federation Hospitalo-Universitaire, INCREASE, Besançon, France.,University of Bourgogne-Franche-Comté, Faculté de Médecine et de Pharmacie, LabEx LipSTIC, Besançon and Dijon, France.,CHU Besançon, Department of Nephrology, Dialysis, and Renal Transplantation, Besançon, France.,CHU Besançon, CIC Biothérapie, INSERM CIC-1431, Besançon, France
| |
Collapse
|
13
|
Zalmaï L, Viailly PJ, Biichle S, Cheok M, Soret L, Angelot-Delettre F, Petrella T, Collonge-Rame MA, Seilles E, Geffroy S, Deconinck E, Daguindau E, Bouyer S, Dindinaud E, Baunin V, Le Garff-Tavernier M, Roos-Weil D, Wagner-Ballon O, Salaun V, Feuillard J, Brun S, Drenou B, Mayeur-Rousse C, Okamba P, Dorvaux V, Tichionni M, Rose J, Rubio MT, Jacob MC, Raggueneau V, Preudhomme C, Saas P, Ferrand C, Adotevi O, Roumier C, Jardin F, Garnache-Ottou F, Renosi F. Plasmacytoid dendritic cells proliferation associated with acute myeloid leukemia: phenotype profile and mutation landscape. Haematologica 2020; 106:3056-3066. [PMID: 33054115 PMCID: PMC8634182 DOI: 10.3324/haematol.2020.253740] [Citation(s) in RCA: 27] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/26/2020] [Indexed: 11/09/2022] Open
Abstract
Neoplasms involving plasmacytoid Dendritic Cells (pDCs) include Blastic pDC Neoplasms (BPDCN) and other pDC proliferations, where pDCs are associated with myeloid malignancies: most frequently Chronic MyeloMonocytic Leukemia (CMML) but also Acute Myeloid Leukemia (AML), hereafter named pDC-AML. We aimed to determine the reactive or neoplastic origin of pDCs in pDC-AML, and their link with the CD34+ blasts, monocytes or conventional DCs (cDCs) associated in the same sample, by phenotypic and molecular analyses (targeted NGS, 70 genes). We compared 15 pDC-AML at diagnosis with 21 BPDCN and 11 normal pDCs from healthy donors. CD45low CD34+ blasts were found in all cases (10-80% of medullar cells), associated with pDCs (4-36%), monocytes in 14 cases (1-10%) and cDCs (2 cases, 4.8-19%). pDCs in pDC-AML harbor a clearly different phenotype from BPDCN: CD4+ CD56- in 100% of cases, most frequently CD303+, CD304+ and CD34+; lower expression of cTCL1 and CD123 with isolated lymphoid markers (CD22/CD7/CD5) in some cases, suggesting a pre-pDC stage. In all cases, pDCs, monocytes and cDC are neoplastic since they harbor the same mutations as CD34+ blasts. RUNX1 is the most commonly mutated gene: detected in all AML with minimal differentiation (M0-AML) but not in the other cases. Despite low number of cases, the systematic association between M0-AML, RUNX1 mutations and an excess of pDC is puzzling. Further evaluation in a larger cohort is required to confirm RUNX1 mutations in pDC-AML with minimal differentiation and to investigate whether it represents a proliferation of blasts with macrophage and DC progenitor potential.
Collapse
Affiliation(s)
- Loria Zalmaï
- Service d'hématologie biologique, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris
| | | | - Sabeha Biichle
- Univ. Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, Besançon
| | - Meyling Cheok
- INSERM U837, CHRU Lille, IRCL Laboratoire d'Hématologie, Centre de Biologie Pathologie, Lille
| | - Lou Soret
- Univ. Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, Besançon
| | - Fanny Angelot-Delettre
- Univ. Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, Besançon
| | - Tony Petrella
- Department of Pathology, University of Montréal, Hôpital Maisonneuve-Rosemont, Montréal, QC
| | | | - Estelle Seilles
- Univ. Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, Besançon
| | - Sandrine Geffroy
- INSERM U837, CHRU Lille, IRCL Laboratoire d'Hématologie, Centre de Biologie Pathologie, Lille, France; Laboratoire d'Hématologie A, Centre de Biologie Pathologie, Boulevard du Pr Leclercq, 59037 Lille
| | | | | | - Sabrina Bouyer
- Service d'Hématologie biologique, CHU La Milétrie, Poitiers
| | | | - Victor Baunin
- Laboratoire du Groupe Hospitalier de La Rochelle-Ré-Aunis, CH de La Rochelle, La Rochelle
| | - Magali Le Garff-Tavernier
- Laboratoire d'Hématologie, Hôpital Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris
| | - Damien Roos-Weil
- Service d'Hématologie Clinique, Sorbonne Université, Hôpital Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris
| | - Orianne Wagner-Ballon
- Département d'Hématologie biologique, Hôpitaux Universitaires Henri Mondor, Assistance Publique-Hôpitaux de Paris (AP-HP), Créteil
| | - Véronique Salaun
- Laboratoire d'Hématologie, CHU de Caen Normandie, Normandie Université, UNICAEN, Caen
| | - Jean Feuillard
- Laboratoire d'hématologie, CHU Dupuytren, avenue Martin Luther King, Limoges
| | - Sophie Brun
- Laboratoire d'Hématologie et Consultations d'Hématologie Biologique, Hôpital Universitaire Carémeau, Nîmes
| | - Bernard Drenou
- Service d'Hématologie, Groupe Hospitalier de la région Mulhouse Sud Alsace, Mulhouse
| | | | - Patricia Okamba
- Laboratoire d'hématologie et auto-immunité, Hôpital de Mercy, CHR de Metz-Thionville
| | | | | | - Johann Rose
- Laboratoire d'hématologie, CH du Mans, Le Mans
| | - Marie Thérèse Rubio
- Service Hématologie, CNRS UMR7365, Biopôle Université de Lorraine, CHRU Nancy, Vandœuvre-lès-Nancy
| | | | - Victoria Raggueneau
- Service de Biologie Médicale, Centre Hospitalier de Versailles A. Mignot, Le Chesnay
| | - Claude Preudhomme
- INSERM U837, CHRU Lille, IRCL Laboratoire d'Hématologie, Centre de Biologie Pathologie, Lille, France; Laboratoire d'Hématologie A, Centre de Biologie Pathologie, Boulevard du Pr Leclercq, 59037 Lille
| | - Philippe Saas
- Univ. Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, Besançon
| | - Christophe Ferrand
- Univ. Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, Besançon
| | - Olivier Adotevi
- Univ. Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, Besançon
| | - Christophe Roumier
- INSERM U837, CHRU Lille, IRCL Laboratoire d'Hématologie, Centre de Biologie Pathologie, Lille, France; Laboratoire d'Hématologie A, Centre de Biologie Pathologie, Boulevard du Pr Leclercq, 59037 Lille
| | | | - Francine Garnache-Ottou
- Univ. Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, Besançon.
| | - Florian Renosi
- Univ. Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, Besançon
| |
Collapse
|
14
|
Gorby C, Sotolongo Bellón J, Wilmes S, Warda W, Pohler E, Fyfe PK, Cozzani A, Ferrand C, Walter MR, Mitra S, Piehler J, Moraga I. Engineered IL-10 variants elicit potent immunomodulatory effects at low ligand doses. Sci Signal 2020; 13:13/649/eabc0653. [PMID: 32934073 DOI: 10.1126/scisignal.abc0653] [Citation(s) in RCA: 41] [Impact Index Per Article: 10.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
Interleukin-10 (IL-10) is a dimeric cytokine with both immunosuppressive and immunostimulatory activities; however, IL-10-based therapies have shown only marginal clinical benefits. Here, we explored whether the stability of the IL-10 receptor complex contributes to the immunomodulatory potency of IL-10. We generated an IL-10 mutant with enhanced affinity for its IL-10Rβ receptor using yeast surface display. Compared to the wild-type cytokine, the affinity-enhanced IL-10 variants recruited IL-10Rβ more efficiently into active cell surface signaling complexes and triggered greater STAT1 and STAT3 activation in human monocytes and CD8+ T cells. These effects, in turn, led to more robust induction of IL-10-mediated gene expression programs at low ligand concentrations in both human cell subsets. IL-10-regulated genes are involved in monocyte energy homeostasis, migration, and trafficking and in CD8+ T cell exhaustion. At nonsaturating doses, IL-10 did not induce key components of its gene expression program, which may explain its lack of efficacy in clinical settings. Our engineered IL-10 variant showed a more robust bioactivity profile than that of wild-type IL-10 at low doses in monocytes and CD8+ T cells. Moreover, CAR-modified T cells expanded with the engineered IL-10 variant displayed superior cytolytic activity than those expanded with wild-type IL-10. Our study provides insights into how IL-10 receptor complex stability fine-tunes IL-10 biology and opens new opportunities to revitalize failed IL-10 therapies.
Collapse
Affiliation(s)
- Claire Gorby
- Division of Cell Signalling and Immunology, School of Life Sciences, University of Dundee, Dundee DD15EH, UK
| | - Junel Sotolongo Bellón
- Department of Biology and Center for Cellular Nanoanalytics (CellNanOs), University of Osnabrück, Barbarastraße 11, 49076 Osnabrück, Germany
| | - Stephan Wilmes
- Division of Cell Signalling and Immunology, School of Life Sciences, University of Dundee, Dundee DD15EH, UK
| | - Walid Warda
- Université Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, RIGHT Interactions Greffon-Hôte-Tumeur/Ingénierie Cellulaire et Génique, F-25000 Besançon, France
| | - Elizabeth Pohler
- Division of Cell Signalling and Immunology, School of Life Sciences, University of Dundee, Dundee DD15EH, UK
| | - Paul K Fyfe
- Division of Cell Signalling and Immunology, School of Life Sciences, University of Dundee, Dundee DD15EH, UK
| | - Adeline Cozzani
- Université de Lille, INSERM UMR1277 CNRS UMR9020-CANTHER and Institut pour la Recherche sur le Cancer de Lille (IRCL), Lille, France
| | - Christophe Ferrand
- Université Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, RIGHT Interactions Greffon-Hôte-Tumeur/Ingénierie Cellulaire et Génique, F-25000 Besançon, France
| | - Mark R Walter
- Department of Microbiology, University of Alabama at Birmingham, Birmingham, AL 35243, USA
| | - Suman Mitra
- Université de Lille, INSERM UMR1277 CNRS UMR9020-CANTHER and Institut pour la Recherche sur le Cancer de Lille (IRCL), Lille, France
| | - Jacob Piehler
- Department of Biology and Center for Cellular Nanoanalytics (CellNanOs), University of Osnabrück, Barbarastraße 11, 49076 Osnabrück, Germany
| | - Ignacio Moraga
- Division of Cell Signalling and Immunology, School of Life Sciences, University of Dundee, Dundee DD15EH, UK.
| |
Collapse
|
15
|
Ferrand C, Martinent G, Bailly N, Giraudeau C, Pothier K, Agli O. Change of depressive symptoms in a French nine-year longitudinal study of aging: Gender differences and relationships between social support, health status and depressive symptoms. Arch Gerontol Geriatr 2020; 89:104059. [PMID: 32334334 DOI: 10.1016/j.archger.2020.104059] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/04/2020] [Revised: 03/20/2020] [Accepted: 03/30/2020] [Indexed: 10/24/2022]
Abstract
OBJECTIVES The aims of this study were to examine the trajectory of depressive symptoms among older French people, to investigate the role of gender in the developmental trajectory of depressive symptoms and to explore whether the linear increase in depressive symptoms might be accentuated or attenuated at time points during which the older adults' scores on social support and health satisfaction scales were higher than their individual averages. METHODS/MATERIALS Data were used from a subsample of older adults living at home who participated in a longitudinal study initiated by researchers from the University of Tours. They were collected at five time points over a 9-year period (T1: 2003; T2: 2005; T3: 2007; T4: 2009; T5: 2011). This study included 707 participants, and multilevel growth curve analysis was used on measures of depressive symptoms, gender differences, social support and health satisfaction. RESULTS Results indicated (1) a significant positive linear effect of age on depressive symptoms; (2) that women reported significantly higher scores of depressive symptoms than men at 63 years old (i.e., intercept) and that this gender difference remained constant across age; (3) that the slope of depressive symptoms appeared to increase at time points during which participants had higher levels of social support and to decrease when they had greater health satisfaction. CONCLUSION This study provides pertinent information about the change of depressive symptoms in older people living at home and particularly highlights the interest in studying gender, social support and health satisfaction.
Collapse
Affiliation(s)
- C Ferrand
- Research Team of Psychology of Ages of Life and Adaptation (EA 2114, PAVéA), University of Tours, France.
| | - G Martinent
- Center for Research and Innovation in Sport, University of Lyon, Villeurbanne, France.
| | - N Bailly
- Research Team of Psychology of Ages of Life and Adaptation (EA 2114, PAVéA), University of Tours, France.
| | - C Giraudeau
- Research Team of Psychology of Ages of Life and Adaptation (EA 2114, PAVéA), University of Tours, France.
| | - K Pothier
- Research Team of Psychology of Ages of Life and Adaptation (EA 2114, PAVéA), University of Tours, France.
| | - O Agli
- Research Team of Psychology of Ages of Life and Adaptation (EA 2114, PAVéA), University of Tours, France.
| |
Collapse
|
16
|
Dahlen E, Sarghi SI, Renosi F, Ferrand C, Collonge-Rame MA, Kuentz P. Post-Essential Thrombocythemia Myelofibrosis and Multiple Isodicentric Y Chromosomes: A Unique Case among a Rare Association. Cytogenet Genome Res 2020; 160:18-21. [PMID: 32008001 DOI: 10.1159/000505844] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 12/20/2019] [Indexed: 11/19/2022] Open
Abstract
Multiple isodicentric Y chromosomes [idic(Y)] is a rare cytogenetic abnormality, most exclusively described in constitutional karyotypes. Only recently has this entity been reported in hematologic neoplasms such as myeloid disorders, albeit these cases remain very scarce. The possible involvement of increasing copies of potential proto-oncogenes located on the multiple idic(Y) led to consider one of them, CRLF2, as a target for kinase inhibitors. We report here, to our knowledge, the first case of multiple idic(Y) in a patient with myelofibrosis secondary to essential thrombocythemia. The patient received ruxolitinib therapy with initial good clinical response.
Collapse
|
17
|
Deschamps M, Decot V, Giverne C, Pinturaud M, Vaissié A, Parquet N, Olivero S, Anne-Claire M, Bay JO, Yakoub-Agha I, Ferrand C. [Requirements for academic production of CAR-T cells in accordance with Good Pharmaceutical Practice (GMP). Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)]. Bull Cancer 2019; 107:S85-S93. [PMID: 31547937 DOI: 10.1016/j.bulcan.2019.08.006] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/17/2019] [Revised: 07/26/2019] [Accepted: 08/14/2019] [Indexed: 11/26/2022]
Abstract
The extraordinary and unexpected success of cellular immunotherapy using genetically engineered T-cells to express a chimeric antigen receptor (CAR) targeting CD19, in the treatment of refractory or relapsing B-hematological malignancies, has provided a real therapeutic hope. Indeed, remission rates reach more than 80 % in patients at a stage, without any other possibilities of treatment, notably in the child's acute lymphoblastic leukemia. These results, initially resulting from academic research, led to Food and Drug accreditation for market access of two innovative autologous therapy drugs, Kimryah® and Yescarta®. Based on the impressive clinical results, mainly so far in hematological malignancies (LAL, MM, LBDGC, etc.), the development of several types of cells expressing a CAR receptor suggests a wide range of future applications, particularly in the field of solid tumors. However, while the development of CAR-T cells now appears to be in the hands of private pharmaceuticals companies, the logistical constraints, the cryopreservation and the very high cost of these personalized medicines may ultimately limit their use. The development of academic productions by CAR-T cells could bypass some of these disadvantages. The strong innovation capacity of healthcare institutions associated with research units allows them to identify the ideal tumor target and efficient performing cells. Thus, authorized production platforms could allow for shorter administration times and reasonable production costs for national health systems. The aim of this workshop is to identify the requirements for the academic production of CAR-T cells, while respecting the research standards useful to establish proof of concept, but also at the preclinical development stage, leading in fine to the manufacture, through an authorized pharmaceutical establishment, of the innovative therapy drug, and in accordance with Good Manufacturing Practice (GMP). The ultimate goal is to make these innovative and high-performance medicines available to as many patients as possible.
Collapse
Affiliation(s)
| | - Véronique Decot
- Unité de thérapie cellulaire et banque de tissus, BSP, UMR CNRS UL7365, 54000 Vandoeuvre-les-Nancy, France
| | - Camille Giverne
- CHU de Rouen, service d'immunologie et biothérapies, Normandie université, UNIROUEN, IRIB Inserm U1234, 76000 Rouen, France
| | | | - Alix Vaissié
- CHRU de Lille, unité d'allogreffe de CSH, maladies du sang, 59037 Lille, France; CHRU de Lille, plateforme de biothérapies, 59000 Lille, France
| | - Nathalie Parquet
- Hôpital Saint-Louis, unité d'aphérèse thérapeutique, 75010 Paris, France
| | - Sylvain Olivero
- CHU de Nice, hôpital Pasteur, unité de thérapie cellulaire et génique, 06000 Nice, France
| | - Mamez Anne-Claire
- Hôpitaux universitaires de Genève, laboratoire de thérapie cellulaire en hémato-oncologie, 1205 Genève, Suisse
| | - Jacques-Olivier Bay
- CHU de Clermont-Ferrand, site Estaing, service de thérapie cellulaire et d'hématologie clinique adulte, 63000 Clermont-Ferrand
| | - Ibrahim Yakoub-Agha
- CHRU de Lille, unité d'allogreffe de CSH, maladies du sang, 59037 Lille, France; Université de Lille 2, Inserm U995, LIRIC, 59000 Lille, France
| | | |
Collapse
|
18
|
Warda W, Neto Da Rocha M, Rim T, Deschamps M, Ferrand C. Stratégie de développement d’un CAR-T-cell ciblant IL1-RAP sécurisé par un gène suicide. Transfus Clin Biol 2019. [DOI: 10.1016/j.tracli.2019.06.303] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
19
|
Fourcade C, Ferrand C, Afzali M, Kruck J, Rogé B. Validation française du Caregiving Strain Questionnaire sur une population de parents d’enfants avec troubles du spectre de l’autisme. Psychologie Française 2019. [DOI: 10.1016/j.psfr.2017.10.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
20
|
Neto Da Rocha M, Trad R, Warda W, Haderbache R, Bouquet L, Nicod C, Deschamps M, Ferrand C. [IL-1RAP as a candidate for CAR T-cells immunotherapy]. Med Sci (Paris) 2019; 35:497-500. [PMID: 31274074 DOI: 10.1051/medsci/2019105] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Affiliation(s)
- Mathieu Neto Da Rocha
- Établissement français du sang de Bourgogne Franche-Comté, Inserm UMR1098 - Université de Bourgogne Franche-Comté, 8, rue du Dr Jean-François-Xavier Girod, BP1937, 25020 Besançon, France
| | - Rim Trad
- Établissement français du sang de Bourgogne Franche-Comté, Inserm UMR1098 - Université de Bourgogne Franche-Comté, 8, rue du Dr Jean-François-Xavier Girod, BP1937, 25020 Besançon, France
| | - Walid Warda
- Établissement français du sang de Bourgogne Franche-Comté, Inserm UMR1098 - Université de Bourgogne Franche-Comté, 8, rue du Dr Jean-François-Xavier Girod, BP1937, 25020 Besançon, France
| | - Rafik Haderbache
- Établissement français du sang de Bourgogne Franche-Comté, Inserm UMR1098 - Université de Bourgogne Franche-Comté, 8, rue du Dr Jean-François-Xavier Girod, BP1937, 25020 Besançon, France
| | - Lucie Bouquet
- Établissement français du sang de Bourgogne Franche-Comté, Inserm UMR1098 - Université de Bourgogne Franche-Comté, 8, rue du Dr Jean-François-Xavier Girod, BP1937, 25020 Besançon, France
| | - Clémentine Nicod
- Établissement français du sang de Bourgogne Franche-Comté, Inserm UMR1098 - Université de Bourgogne Franche-Comté, 8, rue du Dr Jean-François-Xavier Girod, BP1937, 25020 Besançon, France
| | - Marina Deschamps
- Établissement français du sang de Bourgogne Franche-Comté, Inserm UMR1098 - Université de Bourgogne Franche-Comté, 8, rue du Dr Jean-François-Xavier Girod, BP1937, 25020 Besançon, France
| | - Christophe Ferrand
- Établissement français du sang de Bourgogne Franche-Comté, Inserm UMR1098 - Université de Bourgogne Franche-Comté, 8, rue du Dr Jean-François-Xavier Girod, BP1937, 25020 Besançon, France
| |
Collapse
|
21
|
Roussel X, Daguindau E, Berceanu A, Desbrosses Y, Saas P, Ferrand C, Seilles E, Pouthier F, Deconinck E, Larosa F. Altered thymic CD4 + T-cell recovery after allogeneic hematopoietic stem cell transplantation is critical for nocardiosis. Curr Res Transl Med 2019; 67:135-143. [PMID: 31164285 DOI: 10.1016/j.retram.2019.05.001] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/10/2018] [Revised: 05/14/2019] [Accepted: 05/20/2019] [Indexed: 01/29/2023]
Abstract
PURPOSE OF THE STUDY Nocardia affects immunocompromised human host exhibiting an altered cell-mediated immunity. Infectious risk after allogeneic hematopoietic cell transplantation (AHCT) is significantly correlated to the recovery status of donor-derived immune system, especially CD4+ T-cells reconstitution and thymopoiesis. The purpose of this paper is to highlight a lack of cell-mediated immunity recovery for patients presenting a nocardiosis compared to a control cohort. PATIENTS AND METHODS This is a case control retrospective monocentric study. We retrospectively analyzed a monocentric cohort of 15 cases of nocardiosis after AHCT and we explored the degree of patients' immunosuppression by phenotyping circulating lymphoid subpopulations, including NK cells, CD8+ T-cells, CD4+ T-cells and CD19+ B-cells. We focused on CD4+ T-cell subsets to appreciate thymic output, especially on naive CD4+ T-cells (NTE, CD45RA+/RO- CD4+ T-cells) and recent thymic emigrants (RTE, CD4+CD45RA+/RO-/CD31+). Infected patients were paired with a control cohort of patients with identical transplantation characteristics screened on hematological disease, AHCT conditioning, primary graft-versus-host disease (GHVD) prophylaxis, graft type, sex, age, and season at the AHCT and data concerning immunological reconstitution were compared. RESULTS At onset of nocardiosis, circulating lymphocytes and CD4+ T-cells means count were respectively 730/μL and 162/μL. CD8+ T-cells, CD56+ NK cells and CD19+ B-cells means count were respectively 362/μL, 160/μL, 112/μL. CD4+ T-cells subpopulations, naïve CD4+ T-cells production was impaired with NTE and RTE means count at 26/μL and 11/μL respectively. Comparison between nocardiosis cohort and control cohort over time highlight significant lower cellular count for lymphocytes, CD4+ T-cells, NTE and RTE with p = 0.001, p < 0.001, p < 0.001, p < 0.001 respectively. CONCLUSION Immune recovery monitoring follow-up after AHCT is of particular importance to identify patients susceptible to develop Nocardiosis. Efficient microbiological investigations toward Nocardia such PCR should be used in case of compatible clinical presentation.
Collapse
Affiliation(s)
- Xavier Roussel
- University Hospital of Besancon, Department of Hematology, F-25000 Besançon, France.
| | - Etienne Daguindau
- University Hospital of Besancon, Department of Hematology, F-25000 Besançon, France; Univ. Bourgogne Franche-Comté, INSERM, EFS BFC, UMR 1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, F-25000 Besançon, France
| | - Ana Berceanu
- University Hospital of Besancon, Department of Hematology, F-25000 Besançon, France
| | - Yohan Desbrosses
- University Hospital of Besancon, Department of Hematology, F-25000 Besançon, France
| | - Philippe Saas
- Univ. Bourgogne Franche-Comté, INSERM, EFS BFC, UMR 1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, F-25000 Besançon, France
| | - Christophe Ferrand
- Univ. Bourgogne Franche-Comté, INSERM, EFS BFC, UMR 1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, F-25000 Besançon, France
| | - Estelle Seilles
- Univ. Bourgogne Franche-Comté, INSERM, EFS BFC, UMR 1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, F-25000 Besançon, France
| | - Fabienne Pouthier
- Univ. Bourgogne Franche-Comté, INSERM, EFS BFC, UMR 1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, F-25000 Besançon, France
| | - Eric Deconinck
- University Hospital of Besancon, Department of Hematology, F-25000 Besançon, France; Univ. Bourgogne Franche-Comté, INSERM, EFS BFC, UMR 1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, F-25000 Besançon, France
| | - Fabrice Larosa
- University Hospital of Besancon, Department of Hematology, F-25000 Besançon, France
| |
Collapse
|
22
|
Warda W, Larosa F, Neto Da Rocha M, Trad R, Deconinck E, Fajloun Z, Faure C, Caillot D, Moldovan M, Valmary-Degano S, Biichle S, Daguindau E, Garnache-Ottou F, Tabruyn S, Adotevi O, Deschamps M, Ferrand C. CML Hematopoietic Stem Cells Expressing IL1RAP Can Be Targeted by Chimeric Antigen Receptor-Engineered T Cells. Cancer Res 2018; 79:663-675. [PMID: 30514753 DOI: 10.1158/0008-5472.can-18-1078] [Citation(s) in RCA: 52] [Impact Index Per Article: 8.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/25/2018] [Revised: 10/09/2018] [Accepted: 11/29/2018] [Indexed: 12/16/2022]
Abstract
Chronic myeloid leukemia (CML) is a chronic disease resulting in myeloid cell expansion through expression of the BCR-ABL1 fusion transcript. Tyrosine kinase inhibitors (TKI) have significantly increased survival of patients with CML, and deep responders may consider stopping the treatment. However, more than 50% of patients relapse and restart TKI, subsequently suffering unknown toxicity. Because CML is a model immune system-sensitive disease, we hypothesize that chimeric antigen receptor (CAR) T cells targeting IL1 receptor-associated protein (IL1RAP) in quiescent CML stem cells may offer an opportunity for a permanent cure. In this study, we produced and molecularly characterized a specific monoclonal anti-IL1RAP antibody from which fragment antigen-binding nucleotide coding sequences were cloned as a single chain into a lentiviral backbone and secured with the suicide gene iCASP9/rimiducid system. Our CAR T-cell therapy exhibited cytotoxicity against both leukemic stem cells and, to a lesser extent, monocytes expressing IL1RAP, with no apparent effect on the hematopoietic system, including CD34+ stem cells. This suggests IL1RAP as a tumor-associated antigen for immunotherapy cell targeting. IL1RAP CAR T cells were activated in the presence of IL1RAP+ cell lines or primary CML cells, resulting in secretion of proinflammatory cytokines and specifically killing in vitro and in a xenograft murine model. Overall, we demonstrate the proof of concept of a CAR T-cell immunotherapy approach in the context of CML that is applicable for young patients and primary TKI-resistant, intolerant, or allograft candidate patients. SIGNIFICANCE: These findings present the first characterization and proof of concept of a chimeric antigen receptor directed against IL1RAP expressed by leukemic stem cells in the context of CML.
Collapse
Affiliation(s)
- Walid Warda
- INSERM UMR1098, EFS BFC, University of Bourgogne Franche-Comté, Besançon, France.,Laboratory of Applied Biotechnology, Azm Centre for Research in Biotechnology and its Applications, EDST and Faculty of Sciences 3, Lebanese University, Tripoli, Liban
| | - Fabrice Larosa
- Department of Hematology, University Hospital of Besancon, Besancon, France
| | | | - Rim Trad
- INSERM UMR1098, EFS BFC, University of Bourgogne Franche-Comté, Besançon, France
| | - Eric Deconinck
- INSERM UMR1098, EFS BFC, University of Bourgogne Franche-Comté, Besançon, France.,Department of Hematology, University Hospital of Besancon, Besancon, France
| | - Ziad Fajloun
- Laboratory of Applied Biotechnology, Azm Centre for Research in Biotechnology and its Applications, EDST and Faculty of Sciences 3, Lebanese University, Tripoli, Liban
| | - Cyril Faure
- Department of Internal Medicine, Hospital of Haute Saone, Vesoul, France
| | - Denis Caillot
- Department of Hematology, University Hospital of Dijon, Dijon, France
| | - Marius Moldovan
- Department of Internal Medicine, Hospital Nord Franche-Comté, Belfort, France
| | | | - Sabeha Biichle
- INSERM UMR1098, EFS BFC, University of Bourgogne Franche-Comté, Besançon, France
| | - Etienne Daguindau
- INSERM UMR1098, EFS BFC, University of Bourgogne Franche-Comté, Besançon, France.,Department of Hematology, University Hospital of Besancon, Besancon, France
| | | | | | - Olivier Adotevi
- INSERM UMR1098, EFS BFC, University of Bourgogne Franche-Comté, Besançon, France
| | - Marina Deschamps
- INSERM UMR1098, EFS BFC, University of Bourgogne Franche-Comté, Besançon, France
| | - Christophe Ferrand
- INSERM UMR1098, EFS BFC, University of Bourgogne Franche-Comté, Besançon, France.
| |
Collapse
|
23
|
Marton C, Mercier-Letondal P, Deschamps M, Ferrand C, Adotevi O, Borg C, Galaine J, Godet Y. Interest and potential of genetically engineered cord blood derived T cells for cancer immunotherapy. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy485.009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
24
|
Mercier-Letondal P, Marton C, Deschamps M, Ferrand C, Vauchy C, Chenut C, Baguet A, Adotévi O, Borg C, Galaine J, Godet Y. Isolation and Characterization of an HLA-DRB1*04-Restricted HPV16-E7 T Cell Receptor for Cancer Immunotherapy. Hum Gene Ther 2018; 29:1202-1212. [PMID: 30136612 DOI: 10.1089/hum.2018.091] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022] Open
Abstract
High-risk human papillomavirus (HPV) infection is a causal factor in oropharyngeal and gynecological malignancies, and development of HPV-targeted immunotherapy could be used to treat patients with these cancers. T cell-mediated adoptive immunotherapy targeting E6 and E7, two HPV16 proteins consistently expressed in tumor cells, appears to be both attractive and safe. However, isolation of HPV-specific T cells is difficult owing to the low frequency of these cell precursors in the peripheral blood. In addition, HPV-positive cancer cells often down-regulate major histocompatibility complex (MHC) class I expression ex vivo, limiting the efficacy of MHC class I-restricted approaches. Of particular interest is that both CD4 and CD8 T cells can mediate the responses. Given that CD4 T cells play a critical role in coordinating effective antitumor responses, the generation of a T helper response in patients with HPV16-associated malignancies would unleash the ultimate potential of immunotherapy. In this view, T-cell receptor (TCR) gene transfer could be a relevant strategy to generate HPV16-E7-specific and MHC class II-restricted T cells in sufficient numbers. An HPV16-E7/HLA-DRB1*04 TCR has been isolated from a cancer patient with complete response, and retroviral particles encoding this TCR have been produced. The transgenic TCR is highly expressed in transduced T cells, with a functional inducible caspase-9 suicide gene safety cassette. TCR transgenic T cells are HPV16-E770-89 specific and HLA-DRB1*04 restricted, as determined by interferon (IFN)-γ secretion. CD8 and CD4 T cells are equivalently transduced and secrete interleukin-2 and IFN-γ when cultured with appropriate targets. We also demonstrate that TCR transgenic T cells recognize the endogenously processed and presented HPV16-E770-89 peptide. In conclusion, our data indicate that the production of MHC class II-restricted HPV16-E7-specific T cells is feasible through TCR gene transfer and could be used for immunotherapy.
Collapse
Affiliation(s)
- Patricia Mercier-Letondal
- 1 Université Bourgogne Franche-Comté , INSERM, EFS BFC, UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, F-25000 Besançon, France; Department of Medical Oncology, F-25000 Besançon, France
| | - Chrystel Marton
- 1 Université Bourgogne Franche-Comté , INSERM, EFS BFC, UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, F-25000 Besançon, France; Department of Medical Oncology, F-25000 Besançon, France
| | - Marina Deschamps
- 1 Université Bourgogne Franche-Comté , INSERM, EFS BFC, UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, F-25000 Besançon, France; Department of Medical Oncology, F-25000 Besançon, France
| | - Christophe Ferrand
- 1 Université Bourgogne Franche-Comté , INSERM, EFS BFC, UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, F-25000 Besançon, France; Department of Medical Oncology, F-25000 Besançon, France
| | - Charline Vauchy
- 1 Université Bourgogne Franche-Comté , INSERM, EFS BFC, UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, F-25000 Besançon, France; Department of Medical Oncology, F-25000 Besançon, France
| | - Clément Chenut
- 1 Université Bourgogne Franche-Comté , INSERM, EFS BFC, UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, F-25000 Besançon, France; Department of Medical Oncology, F-25000 Besançon, France
| | - Aurélie Baguet
- 2 EA3181, Université Bourgogne Franche-Comté , F-25000 Besançon, France; and Department of Medical Oncology, F-25000 Besançon, France
| | - Olivier Adotévi
- 1 Université Bourgogne Franche-Comté , INSERM, EFS BFC, UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, F-25000 Besançon, France; Department of Medical Oncology, F-25000 Besançon, France .,3 University Hospital of Besançon , Department of Medical Oncology, F-25000 Besançon, France
| | - Christophe Borg
- 1 Université Bourgogne Franche-Comté , INSERM, EFS BFC, UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, F-25000 Besançon, France; Department of Medical Oncology, F-25000 Besançon, France .,3 University Hospital of Besançon , Department of Medical Oncology, F-25000 Besançon, France
| | - Jeanne Galaine
- 1 Université Bourgogne Franche-Comté , INSERM, EFS BFC, UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, F-25000 Besançon, France; Department of Medical Oncology, F-25000 Besançon, France
| | - Yann Godet
- 1 Université Bourgogne Franche-Comté , INSERM, EFS BFC, UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, F-25000 Besançon, France; Department of Medical Oncology, F-25000 Besançon, France
| |
Collapse
|
25
|
Adotevi O, Godet Y, Galaine J, Lakkis Z, Idirene I, Certoux JM, Jary M, Loyon R, Laheurte C, Kim S, Dormoy A, Pouthier F, Barisien C, Fein F, Tiberghien P, Pivot X, Valmary-Degano S, Ferrand C, Morel P, Delabrousse E, Borg C. In situ delivery of allogeneic natural killer cell (NK) combined with Cetuximab in liver metastases of gastrointestinal carcinoma: A phase I clinical trial. Oncoimmunology 2018; 7:e1424673. [PMID: 29721386 DOI: 10.1080/2162402x.2018.1424673] [Citation(s) in RCA: 22] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/29/2017] [Revised: 12/16/2017] [Accepted: 01/03/2018] [Indexed: 01/08/2023] Open
Abstract
Despite successful introduction of NK-based cellular therapy in the treatment of myeloid leukemia, the potential use of NK alloreactivity in solid malignancies is still elusive. We performed a phase I clinical trial to assess the safety and efficacy of in situ delivery of allogeneic NK cells combined with cetuximab in liver metastasis of gastrointestinal origin. The conditioning chemotherapy was administrated before the allogeneic NK cells injection via hepatic artery. Three escalating doses were tested (3.106, 8.106 and 12.106 NK cells/kg) following by a high-dose interleukin-2 (IL-2). Cetuximab was administered intravenously every week for 7 weeks. Nine patients with liver metastases of colorectal or pancreatic cancers were included, three per dose level. Hepatic artery injection was successfully performed in all patients with no report of dose-limiting toxicity. Two patients had febrile aplasia requiring a short-term antibiotherapy. Grade 3/4 anemia and thrombopenia were also observed related to the chemotherapy. Objective clinical responses were documented in 3 patients and among them 2 occurred in patients injected with cell products harboring two KIR ligand mismatches and one in a patient with one KIR ligand mismatch. Immune monitoring revealed that most patients presented an increase but transient of IL-15 and IL-7 cytokines levels one week after chemotherapy. Furthermore, a high expansion of FoxP3+regulatory T cells and PD-1+ T cells was observed in all patients, related to IL-2 administration. Our results demonstrated that combining allogeneic NK cells transfer via intra-hepatic artery, cetuximab and a high-dose IL-2 is feasible, well tolerated and may result in clinical responses.
Collapse
Affiliation(s)
- O Adotevi
- University Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, F-25000 Besançon, France.,University Hospital of Besançon, Department of Medical Oncology, F-25000 Besançon, France
| | - Y Godet
- University Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, F-25000 Besançon, France
| | - J Galaine
- University Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, F-25000 Besançon, France
| | - Z Lakkis
- University Hospital of Besançon, Department of Gastrointestinal and liver surgery, F-25000 Besançon, France
| | - I Idirene
- University Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, F-25000 Besançon, France
| | - J M Certoux
- University Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, F-25000 Besançon, France
| | - M Jary
- University Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, F-25000 Besançon, France.,University Hospital of Besançon, Department of Medical Oncology, F-25000 Besançon, France
| | - R Loyon
- University Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, F-25000 Besançon, France
| | - C Laheurte
- University Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, F-25000 Besançon, France.,Etablissement Français du Sang Bourgogne Franche-Comté, plateforme de BioMonitoring, F-25000 Besançon, France.,INSERM CIC-1431, University Hospital of Besançon, Clinical Investigation Center in Biotherapy, F-25000, Besançon, France
| | - S Kim
- University Hospital of Besançon, Department of Medical Oncology, F-25000 Besançon, France
| | - A Dormoy
- Etablissement Français du Sang Bourgogne Franche-Comté, F-25000 Besançon, France
| | - F Pouthier
- Etablissement Français du Sang Bourgogne Franche-Comté, F-25000 Besançon, France
| | - C Barisien
- Etablissement Français du Sang Bourgogne Franche-Comté, F-25000 Besançon, France
| | - F Fein
- University Hospital of Besançon, Department of Gastroenterology, F-25000 Besançon, France
| | - P Tiberghien
- University Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, F-25000 Besançon, France
| | - X Pivot
- University Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, F-25000 Besançon, France.,University Hospital of Besançon, Department of Medical Oncology, F-25000 Besançon, France
| | - S Valmary-Degano
- University Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, F-25000 Besançon, France.,University Hospital of Besançon, Department of Pathology, F-25000 Besançon, France
| | - C Ferrand
- University Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, F-25000 Besançon, France
| | - P Morel
- Etablissement Français du Sang Bourgogne Franche-Comté, F-25000 Besançon, France
| | - E Delabrousse
- University Hospital of Besançon, Department of Radiology, F-25000, Besançon, France
| | - C Borg
- University Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, F-25000 Besançon, France.,University Hospital of Besançon, Department of Medical Oncology, F-25000 Besançon, France
| |
Collapse
|
26
|
Magne J, Jenvrin A, Chauchet A, Casasnovas O, Donzel A, Jego L, Aral B, Guy J, Nadal N, Vernerey D, Callier P, Garnache-Ottou F, Ferrand C. Potential added value of a RT-qPCR method of SOX 11 expression, in the context of a multidisciplinary diagnostic assessment of B cell malignancies. Exp Hematol Oncol 2018; 7:5. [PMID: 29484276 PMCID: PMC5819690 DOI: 10.1186/s40164-018-0097-6] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/14/2017] [Accepted: 02/02/2018] [Indexed: 01/24/2023] Open
Abstract
Background Expression of SRY [sex-determining region Y]-box11 (SOX11) is specific to mantle cell lymphoma (MCL) and contributes, in conjunction with immunoglobulin variable heavy chain gene mutation status, to the identification of two forms of this disease. Methods The aim of this report was firstly, to design an easy and suitable RT-qPCR method to quantify SOX11 mRNA expression in mantle cell lymphoma and other B cell malignancies with the proper reference gene; secondly, to define the best threshold of relative quantity of SOX11 mRNA in order to reach the best compromise between sensitivity and specificity. Results For best discrimination of MCL and non-MCL groups we determined an area under the curve (AUC) of 0.9750 and a threshold of 1.76 with 100% sensitivity and 88% specificity. AUC and threshold values of respectively 0.91/1.346 [87% sensitivity, 80% specificity] and 0.9525/1.7120 [100% sensitivity, 88% specificity] for GAPDH and RPLP0 respectively denote that the RPLP0 reference gene alone is sufficient for PCR housekeeping gene. Conclusion This work describes an RT-qPCR assay for SOX11 expression in order to better characterize MCL at diagnosis. Further studies on larger cohorts are needed to evaluate this molecular tool, especially for the follow-up of minimal residual disease. Electronic supplementary material The online version of this article (10.1186/s40164-018-0097-6) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- Julien Magne
- 1INSERM, UMR866, Faculté des Sciences de Santé, Univ. Bourgogne Franche-Comté, 21000 Dijon, France
| | - Alizée Jenvrin
- INSERM, EFS BFC, UMR1098, Univ. Bourgogne Franche-Comté, Besançon, 25000 France
| | - Adrien Chauchet
- 3Department of Hematology, University Hospital of Besancon, 25000 Besançon, France
| | - Olivier Casasnovas
- 4Department of Hematology, University Hospital of Dijon, 21000 Dijon, France
| | - Anne Donzel
- 1INSERM, UMR866, Faculté des Sciences de Santé, Univ. Bourgogne Franche-Comté, 21000 Dijon, France
| | - Laurence Jego
- 1INSERM, UMR866, Faculté des Sciences de Santé, Univ. Bourgogne Franche-Comté, 21000 Dijon, France
| | - Bernard Aral
- 1INSERM, UMR866, Faculté des Sciences de Santé, Univ. Bourgogne Franche-Comté, 21000 Dijon, France
| | - Julien Guy
- 1INSERM, UMR866, Faculté des Sciences de Santé, Univ. Bourgogne Franche-Comté, 21000 Dijon, France
| | - Nathalie Nadal
- 1INSERM, UMR866, Faculté des Sciences de Santé, Univ. Bourgogne Franche-Comté, 21000 Dijon, France
| | - Dewi Vernerey
- Univ. Bourgogne Franche-Comté, EA 3181, 25000 Besançon, France
| | - Patrick Callier
- 1INSERM, UMR866, Faculté des Sciences de Santé, Univ. Bourgogne Franche-Comté, 21000 Dijon, France
| | | | - Christophe Ferrand
- INSERM, EFS BFC, UMR1098, Univ. Bourgogne Franche-Comté, Besançon, 25000 France.,Laboratoire de Thérapeutique Immuno-Moléculaire et cellulaire des cancers, INSERM UMR1098, Etablissement Français du Sang Bourgogne/Franche-Comté, 8, rue du Docteur Jean-François-Xavier Girod, 25020 Besançon, France
| |
Collapse
|
27
|
Kroemer M, Spehner L, Mercier-Letondal P, Boullerot L, Kim S, Jary M, Galaine J, Picard E, Ferrand C, Nguyen T, Larosa F, Adotévi O, Godet Y, Borg C. SALL4 oncogene is an immunogenic antigen presented in various HLA-DR contexts. Oncoimmunology 2018; 7:e1412030. [PMID: 29632725 PMCID: PMC5889287 DOI: 10.1080/2162402x.2017.1412030] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/20/2017] [Revised: 11/11/2017] [Accepted: 11/26/2017] [Indexed: 12/13/2022] Open
Abstract
Purpose: To investigate the immunoprevalence of SALL4-derived peptides in healthy volunteers and cancer patients. Experimental Design: A multistep approach including prediction algorithms was used to design in silico SALL4-derived peptides theoretically able to bind on common HLA-DR and HLA-A/B molecules. The presence of T-cell responses after a long term T-cell assay (28 days) against SALL4 was monitored in 14 healthy donors and the presence of T-cell responses after a short term T-cell assay (10 days) was monitored in 67 cancer patients using IFN-γ ELISPOT assay. A T-cell clone specific for the immunoprevalent A18 K-derived peptide was isolated, characterized and used as a tool to characterize the natural processing of A18 K. Results: A SALL4 specific T-cell repertoire was present in healthy donors (8/14) and cancer patients (29/67) after short term T-cell assay. We further identified two immunoprevalant SALL4-derived peptides, R18 A and A18 K, which bind MHC-class II. In parallel, an A18 K specific Th1 clone recognized monocyte derived Dendritic Cell (moDC) loaded with SALL4 containing cell lysate. The level of IFN-γ secreted by specific T-cell clone was greater in presence of moDC loaded with SALL4 containing cell lysate (49.23 ± 14.02%) than with moDC alone (18.03 ± 3.072%) (p = 0.0477) Conclusion: These results show for the first time immunogenicity of SALL4 oncogenic protein-derived peptides, especially A18 K and R18 A peptides and make them potential targets for personalized medicine. Thus, SALL4 possess major characteristics of a tumor antigen.
Collapse
Affiliation(s)
- Marie Kroemer
- University of Bourgogne Franche-Comté (UBFC), INSERM, EFS BFC, UMR1098, Interactions hôte-greffon-tumeur – Ingénierie Cellulaire et Génique, Besançon, France
- Department of pharmacy, University hospital of Besançon, Besançon, France
| | - Laurie Spehner
- University of Bourgogne Franche-Comté (UBFC), INSERM, EFS BFC, UMR1098, Interactions hôte-greffon-tumeur – Ingénierie Cellulaire et Génique, Besançon, France
| | - Patricia Mercier-Letondal
- University of Bourgogne Franche-Comté (UBFC), INSERM, EFS BFC, UMR1098, Interactions hôte-greffon-tumeur – Ingénierie Cellulaire et Génique, Besançon, France
| | - Laura Boullerot
- University of Bourgogne Franche-Comté (UBFC), INSERM, EFS BFC, UMR1098, Interactions hôte-greffon-tumeur – Ingénierie Cellulaire et Génique, Besançon, France
| | - Stefano Kim
- Department of medical oncology, University Hospital of Besançon, Besançon, France
| | - Marine Jary
- University of Bourgogne Franche-Comté (UBFC), INSERM, EFS BFC, UMR1098, Interactions hôte-greffon-tumeur – Ingénierie Cellulaire et Génique, Besançon, France
- Department of medical oncology, University Hospital of Besançon, Besançon, France
| | - Jeanne Galaine
- University of Bourgogne Franche-Comté (UBFC), INSERM, EFS BFC, UMR1098, Interactions hôte-greffon-tumeur – Ingénierie Cellulaire et Génique, Besançon, France
| | - Emilie Picard
- University of Bourgogne Franche-Comté (UBFC), INSERM, EFS BFC, UMR1098, Interactions hôte-greffon-tumeur – Ingénierie Cellulaire et Génique, Besançon, France
| | - Christophe Ferrand
- University of Bourgogne Franche-Comté (UBFC), INSERM, EFS BFC, UMR1098, Interactions hôte-greffon-tumeur – Ingénierie Cellulaire et Génique, Besançon, France
| | - Thierry Nguyen
- Department of medical oncology, University Hospital of Besançon, Besançon, France
| | - Fabrice Larosa
- Department of hematology, University Hospital of Besançon, Besançon, France
| | - Olivier Adotévi
- University of Bourgogne Franche-Comté (UBFC), INSERM, EFS BFC, UMR1098, Interactions hôte-greffon-tumeur – Ingénierie Cellulaire et Génique, Besançon, France
- Department of medical oncology, University Hospital of Besançon, Besançon, France
| | - Yann Godet
- University of Bourgogne Franche-Comté (UBFC), INSERM, EFS BFC, UMR1098, Interactions hôte-greffon-tumeur – Ingénierie Cellulaire et Génique, Besançon, France
| | - Christophe Borg
- University of Bourgogne Franche-Comté (UBFC), INSERM, EFS BFC, UMR1098, Interactions hôte-greffon-tumeur – Ingénierie Cellulaire et Génique, Besançon, France
- Department of medical oncology, University Hospital of Besançon, Besançon, France
| |
Collapse
|
28
|
Dubois V, Alizadeh M, Bourhis JH, Etancelin P, Farchi O, Ferrand C, Goursaud L, Mollet I, Renac V, Varlet P, Yakoub-Agha I, Bay JO. Étude du chimérisme après allogreffe de cellules hématopoïétiques : recommandations de la Société francophone de greffe de moelle et de thérapie cellulaire (SFGM-TC). Bull Cancer 2017; 104:S59-S64. [DOI: 10.1016/j.bulcan.2017.08.010] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/11/2017] [Revised: 07/31/2017] [Accepted: 08/10/2017] [Indexed: 11/30/2022]
|
29
|
Marton C, Letondal P, Deschamps M, Ferrand C, Adotevi O, Borg C, Galaine J, Godet Y. Generation and characterization of cord blood derived T cells redirected with a TCR targeting E7/HLA-DR4 complex. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx711.048] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
30
|
Yakoub-Agha I, Ferrand C, Chalandon Y, Ballot C, Castilla Llorente C, Deschamps M, Gauthier J, Labalette M, Larghero J, Maheux C, Moreau AS, Varlet P, Pétillon MO, Pinturaud M, Rubio MT, Chabannon C. Prérequis nécessaires pour la mise en place de protocoles de recherche clinique évaluant des thérapies cellulaires et géniques par lymphocytes T dotés de récepteur chimérique à l’antigène (CAR T-cells) : recommandations de la Société francophone de greffe de moelle et de thérapie cellulaire (SFGM-TC). Bull Cancer 2017; 104:S43-S58. [DOI: 10.1016/j.bulcan.2017.10.017] [Citation(s) in RCA: 21] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/03/2017] [Revised: 10/23/2017] [Accepted: 10/24/2017] [Indexed: 11/30/2022]
|
31
|
Ferrand C, Féart C, Martinent G, Albinet C, André N, Audiffren M. Dietary patterns in french home-living older adults: Results from the PRAUSE study. Arch Gerontol Geriatr 2017; 74:88-93. [PMID: 29049938 DOI: 10.1016/j.archger.2017.09.003] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2016] [Accepted: 09/06/2017] [Indexed: 10/18/2022]
Abstract
The aim of the present study was to provide descriptive dietary patterns of home-living older adults, and to examine their association with sociodemographic and 'diet-related' variables, and health and psychological factors. Dietary patterns were analyzed using separately cluster analysis for men (N=151,Mage=72.72, SD=8.80, range=56-97) and women (N=251, Mage=76.74, SD=9.95, range=55-97) in 402 older adults aged 55 years and over. Cluster analyses showed four distinct dietary profiles for each gender. In older men, the four distinct dietary clusters were associated with any differences in sociodemographic and 'diet-related' variables, cognitive function, and health and psychological factors. Likewise, in older women, the four distinct dietary clusters were associated with any differences in sociodemographic and 'diet-related' variables'. However in older women, results showed that the cluster 1 "high fish-fruit-vegetable" was associated with a better cognitive function, a better self-rated health and no depressive symptoms, whereas cluster 3 "moderate ready meals" was associated with cognitive decline, slight depression, and poor perceived health. Results emphasize the interest to take into consideration health and psychological factors associated with dietary patterns to better target the vulnerability of individuals and enable an effective prevention.
Collapse
Affiliation(s)
- C Ferrand
- EA 2114, psychology of life ages, University François Rabelais, Tours, France.
| | - C Féart
- ISPED, University Victor Segalen, Bordeaux, France.
| | - G Martinent
- Laboratoire sur les Vulnérabilités et l'Innovation dans le Sport (L-Vis), Université Claude Bernard Lyon 1, Villeurbanne, France.
| | - C Albinet
- Département de psychologie, axe TIME, Institut national Universitaire Champollion, Albi, France; CeRCA, CNRS UMR 7295, University Poitiers, France.
| | - N André
- CeRCA, CNRS UMR 7295, University Poitiers, France.
| | - M Audiffren
- CeRCA, CNRS UMR 7295, University Poitiers, France.
| |
Collapse
|
32
|
Crépin T, Legendre M, Carron C, Courivaud C, Rebibou J, Laheurte C, Ferrand C, Gaiffe E, Vauchy C, Saas P, Ducloux D, Bamoulid J. Immunosénescence et devenir clinique des patients urémiques. Nephrol Ther 2017. [DOI: 10.1016/j.nephro.2017.08.071] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
33
|
Etienne-Grimaldi MC, Boyer JC, Beroud C, Mbatchi L, van Kuilenburg A, Bobin-Dubigeon C, Thomas F, Chatelut E, Merlin JL, Pinguet F, Ferrand C, Meijer J, Evrard A, Llorca L, Romieu G, Follana P, Bachelot T, Chaigneau L, Pivot X, Dieras V, Largillier R, Mousseau M, Goncalves A, Roché H, Bonneterre J, Servent V, Dohollou N, Château Y, Chamorey E, Desvignes JP, Salgado D, Ferrero JM, Milano G. New advances in DPYD genotype and risk of severe toxicity under capecitabine. PLoS One 2017; 12:e0175998. [PMID: 28481884 PMCID: PMC5421769 DOI: 10.1371/journal.pone.0175998] [Citation(s) in RCA: 70] [Impact Index Per Article: 10.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/02/2016] [Accepted: 04/04/2017] [Indexed: 12/29/2022] Open
Abstract
Background Deficiency in dihydropyrimidine dehydrogenase (DPD) enzyme is the main cause of severe and lethal fluoropyrimidine-related toxicity. Various approaches have been developed for DPD-deficiency screening, including DPYD genotyping and phenotyping. The goal of this prospective observational study was to perform exhaustive exome DPYD sequencing and to examine relationships between DPYD variants and toxicity in advanced breast cancer patients receiving capecitabine. Methods Two-hundred forty-three patients were analysed (88.5% capecitabine monotherapy). Grade 3 and grade 4 capecitabine-related digestive and/or neurologic and/or hemato-toxicities were observed in 10.3% and 2.1% of patients, respectively. DPYD exome, along with flanking intronic regions 3’UTR and 5’UTR, were sequenced on MiSeq Illumina. DPD phenotype was assessed by pre-treatment plasma uracil (U) and dihydrouracil (UH2) measurement. Results Among the 48 SNPs identified, 19 were located in coding regions, including 3 novel variations, each observed in a single patient (among which, F100L and A26T, both pathogenic in silico). Combined analysis of deleterious variants *2A, I560S (*13) and D949V showed significant association with grade 3–4 toxicity (sensitivity 16.7%, positive predictive value (PPV) 71.4%, relative risk (RR) 6.7, p<0.001) but not with grade 4 toxicity. Considering additional deleterious coding variants D342G, S492L, R592W and F100L increased the sensitivity to 26.7% for grade 3–4 toxicity (PPV 72.7%, RR 7.6, p<0.001), and was significantly associated with grade 4 toxicity (sensitivity 60%, PPV 27.3%, RR 31.4, p = 0.001), suggesting the clinical relevance of extended targeted DPYD genotyping. As compared to extended genotype, combining genotyping (7 variants) and phenotyping (U>16 ng/ml) did not substantially increase the sensitivity, while impairing PPV and RR. Conclusions Exploring an extended set of deleterious DPYD variants improves the performance of DPYD genotyping for predicting both grade 3–4 and grade 4 toxicities (digestive and/or neurologic and/or hematotoxicities) related to capecitabine, as compared to conventional genotyping restricted to consensual variants *2A, *13 and D949V.
Collapse
Affiliation(s)
| | | | - Christophe Beroud
- Aix-Marseille University, INSERM UMR S910, GMGF, Marseille, France
- APHM Hôpital Timone, Laboratoire de Génétique Moléculaire, Marseille, France
| | - Litaty Mbatchi
- Faculté de Pharmacie de Montpellier, Montpellier, France
| | - André van Kuilenburg
- Laboratory Genetic Metabolic Diseases, Academic Medical Center, Amsterdam,The Netherlands
| | | | - Fabienne Thomas
- Institut Claudius-Regaud, CRCT, Université de Toulouse, Inserm, UPS, Toulouse, France
| | - Etienne Chatelut
- Institut Claudius-Regaud, CRCT, Université de Toulouse, Inserm, UPS, Toulouse, France
| | - Jean-Louis Merlin
- Institut de Cancérologie de Lorraine, UMR CNRS 7039 CRAN, Université de Lorraine, Nancy, France
| | | | | | - Judith Meijer
- Laboratory Genetic Metabolic Diseases, Academic Medical Center, Amsterdam,The Netherlands
| | | | | | | | | | | | | | | | | | | | | | | | - Henri Roché
- Institut Claudius-Regaud, CRCT, Université de Toulouse, Inserm, UPS, Toulouse, France
| | | | | | | | | | | | | | - David Salgado
- Aix-Marseille University, INSERM UMR S910, GMGF, Marseille, France
| | | | | |
Collapse
|
34
|
Wu T, Heuillard E, Lindner V, Bou About G, Ignat M, Dillenseger JP, Anton N, Dalimier E, Gossé F, Fouré G, Blindauer F, Giraudeau C, El-Saghire H, Bouhadjar M, Calligaro C, Sorg T, Choquet P, Vandamme T, Ferrand C, Marescaux J, Baumert TF, Diana M, Pessaux P, Robinet E. Multimodal imaging of a humanized orthotopic model of hepatocellular carcinoma in immunodeficient mice. Sci Rep 2016; 6:35230. [PMID: 27739457 PMCID: PMC5064389 DOI: 10.1038/srep35230] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/11/2015] [Accepted: 09/15/2016] [Indexed: 02/07/2023] Open
Abstract
The development of multimodal strategies for the treatment of hepatocellular carcinoma requires tractable animal models allowing for advanced in vivo imaging. Here, we characterize an orthotopic hepatocellular carcinoma model based on the injection of luciferase-expressing human hepatoma Huh-7 (Huh-7-Luc) cells in immunodeficient mice. Luciferase allows for an easy repeated monitoring of tumor growth by in vivo bioluminescence. The intrahepatic injection was more efficient than intrasplenic or intraportal injection in terms of survival, rate of orthotopic engraftment, and easiness. A positive correlation between luciferase activity and tumor size, evaluated by Magnetic Resonance Imaging, allowed to define the endpoint value for animal experimentation with this model. Response to standard of care, sorafenib or doxorubicin, were similar to those previously reported in the literature, with however a strong toxicity of doxorubicin. Tumor vascularization was visible by histology seven days after Huh-7-Luc transplantation and robustly developed at day 14 and day 21. The model was used to explore different imaging modalities, including microtomography, probe-based confocal laser endomicroscopy, full-field optical coherence tomography, and ultrasound imaging. Tumor engraftment was similar after echo-guided intrahepatic injection as after laparotomy. Collectively, this orthotopic hepatocellular carcinoma model enables the in vivo evaluation of chemotherapeutic and surgical approaches using multimodal imaging.
Collapse
Affiliation(s)
- Tao Wu
- INSERM, U 1110, 67000 Strasbourg, France.,University of Strasbourg, 67000 Strasbourg, France.,Department of Hepatobiliary and Pancreatic Surgery, Second Affiliated Hospital of Kunming Medical University, Kunming, 650500, Yunnan, People's Republic of China
| | - Emilie Heuillard
- INSERM, U 1110, 67000 Strasbourg, France.,University of Strasbourg, 67000 Strasbourg, France.,IHU-Strasbourg, Institute of Image-Guided Surgery, 67000 Strasbourg, France
| | - Véronique Lindner
- Pathology Department, University Hospital of Strasbourg, 67000 Strasbourg, France
| | | | - Mihaela Ignat
- Pôle Hépatodigestif, Unité Hépatologie, Hôpitaux Universitaires de Strasbourg, 67000 Strasbourg, France.,Research Institute against Cancer of the Digestive System (IRCAD), 67000 Strasbourg, France
| | - Jean-Philippe Dillenseger
- University of Strasbourg, 67000 Strasbourg, France.,Functional Unit 6237, Preclinical Imaging, Hôpitaux Universitaires de Strasbourg, 67000 Strasbourg, France.,National Center for Scientific Research (CNRS), ICube, MMB team, 67000 Strasbourg, France.,Medical Faculty, Fédération de Médecine Translationnelle de Strasbourg (FMTS), 67000 Strasbourg, France
| | - Nicolas Anton
- University of Strasbourg, 67000 Strasbourg, France.,National Center for Scientific Research (CNRS), UMR 7199, 67400 Illkirch, France
| | | | - Francine Gossé
- INSERM, U 1110, 67000 Strasbourg, France.,University of Strasbourg, 67000 Strasbourg, France
| | - Gael Fouré
- IHU-Strasbourg, Institute of Image-Guided Surgery, 67000 Strasbourg, France
| | - Franck Blindauer
- IHU-Strasbourg, Institute of Image-Guided Surgery, 67000 Strasbourg, France
| | - Céline Giraudeau
- IHU-Strasbourg, Institute of Image-Guided Surgery, 67000 Strasbourg, France
| | - Hussein El-Saghire
- INSERM, U 1110, 67000 Strasbourg, France.,University of Strasbourg, 67000 Strasbourg, France
| | - Mourad Bouhadjar
- IHU-Strasbourg, Institute of Image-Guided Surgery, 67000 Strasbourg, France
| | - Cynthia Calligaro
- IHU-Strasbourg, Institute of Image-Guided Surgery, 67000 Strasbourg, France
| | - Tania Sorg
- Mouse Clinical Institute, 67400 Illkirch, France
| | - Philippe Choquet
- University of Strasbourg, 67000 Strasbourg, France.,Functional Unit 6237, Preclinical Imaging, Hôpitaux Universitaires de Strasbourg, 67000 Strasbourg, France.,National Center for Scientific Research (CNRS), ICube, MMB team, 67000 Strasbourg, France.,Medical Faculty, Fédération de Médecine Translationnelle de Strasbourg (FMTS), 67000 Strasbourg, France
| | - Thierry Vandamme
- University of Strasbourg, 67000 Strasbourg, France.,National Center for Scientific Research (CNRS), UMR 7199, 67400 Illkirch, France
| | - Christophe Ferrand
- French Blood Agency Bourgogne/Franche-Comté, 25000 Besançon, France.,INSERM, U 1098, 25000 Besançon, France.,Université de Franche-Comté, 25000 Besançon, France
| | - Jacques Marescaux
- IHU-Strasbourg, Institute of Image-Guided Surgery, 67000 Strasbourg, France.,Pôle Hépatodigestif, Unité Hépatologie, Hôpitaux Universitaires de Strasbourg, 67000 Strasbourg, France.,Research Institute against Cancer of the Digestive System (IRCAD), 67000 Strasbourg, France
| | - Thomas F Baumert
- INSERM, U 1110, 67000 Strasbourg, France.,University of Strasbourg, 67000 Strasbourg, France.,IHU-Strasbourg, Institute of Image-Guided Surgery, 67000 Strasbourg, France.,Pôle Hépatodigestif, Unité Hépatologie, Hôpitaux Universitaires de Strasbourg, 67000 Strasbourg, France
| | - Michele Diana
- IHU-Strasbourg, Institute of Image-Guided Surgery, 67000 Strasbourg, France.,Research Institute against Cancer of the Digestive System (IRCAD), 67000 Strasbourg, France
| | - Patrick Pessaux
- INSERM, U 1110, 67000 Strasbourg, France.,University of Strasbourg, 67000 Strasbourg, France.,IHU-Strasbourg, Institute of Image-Guided Surgery, 67000 Strasbourg, France.,Pôle Hépatodigestif, Unité Hépatologie, Hôpitaux Universitaires de Strasbourg, 67000 Strasbourg, France.,Research Institute against Cancer of the Digestive System (IRCAD), 67000 Strasbourg, France
| | - Eric Robinet
- INSERM, U 1110, 67000 Strasbourg, France.,University of Strasbourg, 67000 Strasbourg, France.,IHU-Strasbourg, Institute of Image-Guided Surgery, 67000 Strasbourg, France
| |
Collapse
|
35
|
Loyon R, Picard E, Mauvais O, Queiroz L, Mougey V, Pallandre JR, Galaine J, Mercier-Letondal P, Kellerman G, Chaput N, Wijdenes J, Adotévi O, Ferrand C, Romero P, Godet Y, Borg C. IL-21-Induced MHC Class II+ NK Cells Promote the Expansion of Human Uncommitted CD4+ Central Memory T Cells in a Macrophage Migration Inhibitory Factor-Dependent Manner. J Immunol 2016; 197:85-96. [PMID: 27233967 DOI: 10.4049/jimmunol.1501147] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/20/2015] [Accepted: 04/18/2016] [Indexed: 01/15/2023]
Abstract
NK cells are critical for innate immunity-mediated protection. The main roles of NK cells rely on their cytotoxic functions or depend on the tuning of Th1 adaptive immunity by IFN-γ. However, the precise influence of inflammatory cytokines on NK cell and CD4 T lymphocyte interactions was never investigated. In this study, we provide evidence that IL-21, a cytokine produced during chronic inflammation or infectious diseases, promotes the differentiation of a specific subset of NK cells coexpressing CD86 and HLA-DR and lacking NKp44. More importantly, IL-21-propagated HLA-DR(+) NK cells produce macrophage migration inhibitory factor and provide costimulatory signaling during naive CD4(+) T cell priming inducing the differentiation of uncommitted central memory T cells. Central memory T cells expanded in the presence of HLA-DR(+) NK cells are CXCR3(+)CCR6(-)CCR4(-)CXCR5(-) and produce IL-2, as well as low levels of TNF-α. Costimulation of CD4(+) T cells by HLA-DR(+) NK cells prevents the acquisition of effector memory phenotype induced by IL-2. Moreover, we identified this population of NK HLA-DR(+) macrophage migration inhibitory factor(+) cells in inflammatory human appendix. Collectively, these results demonstrate a novel function for IL-21 in tuning NK and CD4(+) T cell interactions promoting a specific expansion of central memory lymphocytes.
Collapse
Affiliation(s)
- Romain Loyon
- INSERM Unit 1098, University of Franche-Comté, 25000 Besançon, France
| | - Emilie Picard
- INSERM Unit 1098, University of Franche-Comté, 25000 Besançon, France
| | - Olivier Mauvais
- Department of Head and Neck Surgery, University Hospital of Besançon, 25000 Besançon, France
| | - Lise Queiroz
- INSERM Unit 1098, University of Franche-Comté, 25000 Besançon, France; Clinical Investigation Center for Biotherapies, 25000 Besançon, France
| | - Virginie Mougey
- INSERM Unit 1098, University of Franche-Comté, 25000 Besançon, France; Etablissement Français du Sang, 25000 Besançon, France
| | - Jean-René Pallandre
- INSERM Unit 1098, University of Franche-Comté, 25000 Besançon, France; INSERM Unit 1007, University of Paris Descartes, 75270 Paris, France
| | - Jeanne Galaine
- INSERM Unit 1098, University of Franche-Comté, 25000 Besançon, France
| | - Patricia Mercier-Letondal
- INSERM Unit 1098, University of Franche-Comté, 25000 Besançon, France; Etablissement Français du Sang, 25000 Besançon, France
| | | | - Nathalie Chaput
- INSERM Unit 1015, Gustave Roussy Cancer Campus, 94805 Villejuif, France
| | - John Wijdenes
- INSERM Unit 1098, University of Franche-Comté, 25000 Besançon, France
| | - Olivier Adotévi
- INSERM Unit 1098, University of Franche-Comté, 25000 Besançon, France; Clinical Investigation Center for Biotherapies, 25000 Besançon, France; Department of Medical Oncology, University Hospital of Besançon, 25000 Besançon, France; and
| | - Christophe Ferrand
- INSERM Unit 1098, University of Franche-Comté, 25000 Besançon, France; Etablissement Français du Sang, 25000 Besançon, France
| | - Pedro Romero
- Ludwig Center for Cancer Research of the University of Lausanne, Lausanne 1066, Switzerland
| | - Yann Godet
- INSERM Unit 1098, University of Franche-Comté, 25000 Besançon, France
| | - Christophe Borg
- INSERM Unit 1098, University of Franche-Comté, 25000 Besançon, France; Clinical Investigation Center for Biotherapies, 25000 Besançon, France; Etablissement Français du Sang, 25000 Besançon, France; Department of Medical Oncology, University Hospital of Besançon, 25000 Besançon, France; and
| |
Collapse
|
36
|
Samson M, Ly KH, Tournier B, Janikashvili N, Trad M, Ciudad M, Gautheron A, Devilliers H, Quipourt V, Maurier F, Meaux-Ruault N, Magy-Bertrand N, Manckoundia P, Ornetti P, Maillefert JF, Besancenot JF, Ferrand C, Mesturoux L, Labrousse F, Fauchais AL, Saas P, Martin L, Audia S, Bonnotte B. Involvement and prognosis value of CD8(+) T cells in giant cell arteritis. J Autoimmun 2016; 72:73-83. [PMID: 27236507 DOI: 10.1016/j.jaut.2016.05.008] [Citation(s) in RCA: 45] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/14/2016] [Revised: 05/09/2016] [Accepted: 05/11/2016] [Indexed: 11/18/2022]
Abstract
CD8(+) T cells participate in the pathogenesis of some vasculitides. However, little is known about their role in Giant Cell Arteritis (GCA). This study was conducted to investigate CD8(+) T cell involvement in the pathogenesis of GCA. Analyses were performed at diagnosis and after 3 months of glucocorticoid treatment in 34 GCA patients and 26 age-matched healthy volunteers. Percentages of CD8(+) T-cell subsets, spectratype analysis of the TCR Vβ families of CD8(+) T cells, levels of cytokines and chemokines and immunohistochemistry of temporal artery biopsies (TAB) were assessed. Among total CD8(+) T cells, percentages of circulating cytotoxic CD8 T lymphocytes (CTL, CD3(+)CD8(+)perforin(+)granzymeB(+)), Tc17 (CD3(+)CD8(+)IL-17(+)), CD63(+)CD8(+) T cells and levels of soluble granzymes A and B were higher in patients than in controls, whereas the percentage of Tc1 cells (CD3(+)CD8(+)IFN-γ(+)) was similar. Moreover, CD8(+) T cells displayed a restricted TCR repertoire in GCA patients. Percentages of circulating CTL, Tc17 and soluble levels of granzymes A and B decreased after treatment. CXCR3 expression on CD8(+) T cells and its serum ligands (CXCL9, -10, -11) were higher in patients. Analyses of TAB revealed high expression of CXCL9 and -10 associated with infiltration by CXCR3(+)CD8(+) T cells expressing granzyme B and TiA1. The intensity of the CD8 T-cell infiltrate in TAB was predictive of the severity of the disease. This study demonstrates the implication and the prognostic value of CD8(+) T-cells in GCA and suggests that CD8(+) T-cells are recruited within the vascular wall through an interaction between CXCR3 and its ligands.
Collapse
Affiliation(s)
- Maxime Samson
- INSERM, UMR1098, University of Bourgogne Franche-Comté, FHU INCREASE, France; Department of Internal Medicine and Clinical Immunology, François Mitterrand Hospital, Dijon University Hospital, Dijon, France
| | - Kim Heang Ly
- Department of Internal Medicine, Limoges University Hospital, Limoges, France
| | | | - Nona Janikashvili
- INSERM, UMR1098, University of Bourgogne Franche-Comté, FHU INCREASE, France
| | - Malika Trad
- INSERM, UMR1098, University of Bourgogne Franche-Comté, FHU INCREASE, France
| | - Marion Ciudad
- INSERM, UMR1098, University of Bourgogne Franche-Comté, FHU INCREASE, France
| | | | - Hervé Devilliers
- Department of Internal Medicine and Systemic Diseases, François Mitterrand Hospital, Dijon University Hospital, Dijon, France
| | - Valérie Quipourt
- Department of Geriatric Internal Medicine, Dijon University Hospital, Dijon, France
| | - François Maurier
- Department of Internal Medicine, HP Metz Belle Isle Hospital, Metz, France
| | - Nadine Meaux-Ruault
- Department of Internal Medicine, Besançon University Hospital, Besançon, France
| | | | - Patrick Manckoundia
- Department of Geriatric Internal Medicine, Dijon University Hospital, Dijon, France
| | - Paul Ornetti
- Department of Rheumatology, François Mitterrand Hospital, Dijon University Hospital, Dijon, France; INSERM 1093, plateforme d'investigation technologique, Dijon University Hospital, 21000 Dijon, France
| | - Jean-Francis Maillefert
- Department of Rheumatology, François Mitterrand Hospital, Dijon University Hospital, Dijon, France
| | - Jean-François Besancenot
- Department of Internal Medicine and Systemic Diseases, François Mitterrand Hospital, Dijon University Hospital, Dijon, France
| | - Christophe Ferrand
- INSERM, UMR1098, University of Bourgogne Franche-Comté, FHU INCREASE, France
| | - Laura Mesturoux
- Department of Pathology, Limoges University Hospital, Limoges, France
| | | | - Anne-Laure Fauchais
- Department of Internal Medicine, Limoges University Hospital, Limoges, France
| | - Philippe Saas
- INSERM, UMR1098, University of Bourgogne Franche-Comté, FHU INCREASE, France
| | - Laurent Martin
- Department of Pathology, François Mitterrand Hospital, Dijon University Hospital, Dijon, France
| | - Sylvain Audia
- INSERM, UMR1098, University of Bourgogne Franche-Comté, FHU INCREASE, France; Department of Internal Medicine and Clinical Immunology, François Mitterrand Hospital, Dijon University Hospital, Dijon, France
| | - Bernard Bonnotte
- INSERM, UMR1098, University of Bourgogne Franche-Comté, FHU INCREASE, France; Department of Internal Medicine and Clinical Immunology, François Mitterrand Hospital, Dijon University Hospital, Dijon, France.
| |
Collapse
|
37
|
Gamonet C, Bole-Richard E, Delherme A, Aubin F, Toussirot E, Garnache-Ottou F, Godet Y, Ysebaert L, Tournilhac O, Caroline D, Larosa F, Deconinck E, Saas P, Borg C, Deschamps M, Ferrand C. New CD20 alternative splice variants: molecular identification and differential expression within hematological B cell malignancies. Exp Hematol Oncol 2016; 5:7. [PMID: 26937306 PMCID: PMC4774009 DOI: 10.1186/s40164-016-0036-3] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/20/2015] [Accepted: 02/13/2016] [Indexed: 02/07/2023] Open
Abstract
BACKGROUND CD20 is a B cell lineage-specific marker expressed by normal and leukemic B cells and targeted by several antibody immunotherapies. We have previously shown that the protein from a CD20 mRNA splice variant (D393-CD20) is expressed at various levels in leukemic B cells or lymphoma B cells but not in resting, sorted B cells from the peripheral blood of healthy donors. RESULTS Western blot (WB) analysis of B malignancy primary samples showed additional CD20 signals. Deep molecular PCR analysis revealed four new sequences corresponding to in-frame CD20 splice variants (D657-CD20, D618-CD20, D480-CD20, and D177-CD20) matching the length of WB signals. We demonstrated that the cell spliceosome machinery can process ex vivo D480-, D657-, and D618-CD20 transcript variants by involving canonical sites associated with cryptic splice sites. Results of specific and quantitative RT-PCR assays showed that these CD20 splice variants are differentially expressed in B malignancies. Moreover, Epstein-Barr virus (EBV) transformation modified the CD20 splicing profile and mainly increased the D393-CD20 variant transcripts. Finally, investigation of three cohorts of chronic lymphocytic leukemia (CLL) patients showed that the total CD20 splice variant expression was higher in a stage B and C sample collection compared to routinely collected CLL samples or relapsed refractory stage A, B, or C CLL. CONCLUSION The involvement of these newly discovered alternative CD20 transcript variants in EBV transformation makes them interesting molecular indicators, as does their association with oncogenesis rather than non-oncogenic B cell diseases, differential expression in B cell malignancies, and correlation with CLL stage and some predictive CLL markers. This potential should be investigated in further studies.
Collapse
Affiliation(s)
- Clémentine Gamonet
- INSERM UMR1098, Établissement Français du Sang Bourgogne Franche Comté, Université de Franche-Comté, SFR FED4234, 25020 Besançon, France
| | - Elodie Bole-Richard
- INSERM UMR1098, Établissement Français du Sang Bourgogne Franche Comté, Université de Franche-Comté, SFR FED4234, 25020 Besançon, France
| | - Aurélia Delherme
- INSERM UMR1098, Établissement Français du Sang Bourgogne Franche Comté, Université de Franche-Comté, SFR FED4234, 25020 Besançon, France
| | - François Aubin
- EA3181 et Service de Dermatologie, Université de Franche Comté, CHU de Besançon, Besançon, France
| | - Eric Toussirot
- EA3181 et Service de Dermatologie, Université de Franche Comté, CHU de Besançon, Besançon, France ; CHRU, Department of Rheumatology, Université de Franche-Comté EA 4266, INSERM CIC-1431, 25000 Besançon, France ; EA 4266, Université de Franche-Comté, Besançon, France
| | - Francine Garnache-Ottou
- INSERM UMR1098, Établissement Français du Sang Bourgogne Franche Comté, Université de Franche-Comté, SFR FED4234, 25020 Besançon, France ; EA3181 et Service de Dermatologie, Université de Franche Comté, CHU de Besançon, Besançon, France
| | - Yann Godet
- INSERM UMR1098, Établissement Français du Sang Bourgogne Franche Comté, Université de Franche-Comté, SFR FED4234, 25020 Besançon, France ; EA3181 et Service de Dermatologie, Université de Franche Comté, CHU de Besançon, Besançon, France
| | - Loïc Ysebaert
- Inserm U1037, Université Toulouse 3-ERL CNRS, CHU Purpan, Toulouse, France
| | - Olivier Tournilhac
- Hématologie Clinique, CHU Estaing, 1 Place Lucie Aubrac, 63003 Clermont-Ferrand Cedex 1, France
| | | | - Fabrice Larosa
- INSERM UMR1098, Établissement Français du Sang Bourgogne Franche Comté, Université de Franche-Comté, SFR FED4234, 25020 Besançon, France ; Hematology Department, CHU Jean Minjoz, 25020 Besançon, France
| | - Eric Deconinck
- INSERM UMR1098, Établissement Français du Sang Bourgogne Franche Comté, Université de Franche-Comté, SFR FED4234, 25020 Besançon, France ; EA3181 et Service de Dermatologie, Université de Franche Comté, CHU de Besançon, Besançon, France ; Hematology Department, CHU Jean Minjoz, 25020 Besançon, France
| | - Philippe Saas
- INSERM UMR1098, Établissement Français du Sang Bourgogne Franche Comté, Université de Franche-Comté, SFR FED4234, 25020 Besançon, France ; EA3181 et Service de Dermatologie, Université de Franche Comté, CHU de Besançon, Besançon, France
| | - Christophe Borg
- INSERM UMR1098, Établissement Français du Sang Bourgogne Franche Comté, Université de Franche-Comté, SFR FED4234, 25020 Besançon, France ; EA3181 et Service de Dermatologie, Université de Franche Comté, CHU de Besançon, Besançon, France
| | - Marina Deschamps
- INSERM UMR1098, Établissement Français du Sang Bourgogne Franche Comté, Université de Franche-Comté, SFR FED4234, 25020 Besançon, France
| | - Christophe Ferrand
- INSERM UMR1098, Établissement Français du Sang Bourgogne Franche Comté, Université de Franche-Comté, SFR FED4234, 25020 Besançon, France ; Laboratoire de Thérapeutique Immuno-Moléculaire et cellulaire des cancers, INSERM UMR1098, Etablissement Français du Sang-Bourgogne/Franche-Comté, 8, rue du Docteur Jean-François-Xavier Girod, 25020 Besançon Cedex, France
| |
Collapse
|
38
|
Laheurte C, Galaine J, Beziaud L, Dosset M, Kerzerho J, Jacquemard C, Gaugler B, Ferrand C, Dormoy A, Aubin F, Jacoulet P, Westeel V, Borg C, Tartour E, Godet Y, Maillère B, Adotévi O. Immunoprevalence and magnitude of HLA-DP4 versus HLA-DR-restricted spontaneous CD4(+) Th1 responses against telomerase in cancer patients. Oncoimmunology 2016; 5:e1137416. [PMID: 27467955 DOI: 10.1080/2162402x.2015.1137416] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/02/2015] [Revised: 12/18/2015] [Accepted: 12/28/2015] [Indexed: 10/22/2022] Open
Abstract
Cumulative evidence supports that CD4(+) Th1 cells play a key role in antitumor immunity. We previously reported the presence of spontaneous HLA-DR-restricted CD4(+) Th1 responses against telomerase reverse transcriptase (TERT) in various cancers by using promiscuous HLA-DR epitopes. Here, we described novel highly immunogenic HLA-DP4-binding epitopes from TERT named TERT541-555, TERT573-587, TERT613-627 and TERT911-925 and addressed the question about the immunoprevalence and magnitude of the naturally occurring antitumor CD4(+) T cell responses restricted by HLA-DP4 or HLA-DR, the two most common HLA class II. Direct comparative study of spontaneous anti-TERT CD4(+) T cell responses in a cohort of 87 lung cancer patients showed that HLA-DP4 and HLA-DR sustained specific Th1 responses in 10.1% and 25.2% of cancer patients respectively (p = 0.01). The magnitude of the HLA-DR-restricted responses was two to three times significantly higher than HLA-DP one (p = 0.005). Similar results were found in other cancers such as melanoma, breast cancer, renal cell carcinoma and colon cancer. Thus, our results describe for the first time in a large cohort of cancer patients a high immunoprevalence of HLA-DR-restricted spontaneous anti-TERT Th1 immunity compared to HLA-DP restriction. These results provide a new tool for comprehensive monitoring of antitumor CD4(+) Th1 response in various cancers.
Collapse
Affiliation(s)
- Caroline Laheurte
- INSERM, UMR1098, LabEx LipSTIC, Besançon, France; EFS Bourgogne Franche-Comté, Plateforme de Biomonitoring, INSERM CIC1431, Besançon, France
| | - Jeanne Galaine
- INSERM, UMR1098, LabEx LipSTIC, Besançon, France; Univ. Bourgogne Franche-Comté, UMR1098, Besançon, France
| | - Laurent Beziaud
- INSERM, UMR1098, LabEx LipSTIC, Besançon, France; Univ. Bourgogne Franche-Comté, UMR1098, Besançon, France
| | - Magalie Dosset
- INSERM, UMR1098, LabEx LipSTIC, Besançon, France; Univ. Bourgogne Franche-Comté, UMR1098, Besançon, France
| | - Jerome Kerzerho
- CEA, iBiTecS, Service d'Ingénierie Moléculaire des Protéines (SIMOPRO), Labex LERMIT, Labex VRI , Gif Sur Yvette, France
| | - Claire Jacquemard
- EFS Bourgogne Franche-Comté, Plateforme de Biomonitoring, INSERM CIC1431 , Besançon, France
| | - Béatrice Gaugler
- INSERM, UMR1098, LabEx LipSTIC, Besançon, France; EFS Bourgogne Franche-Comté, Plateforme de Biomonitoring, INSERM CIC1431, Besançon, France; Univ. Bourgogne Franche-Comté, UMR1098, Besançon, France
| | - Christophe Ferrand
- INSERM, UMR1098, LabEx LipSTIC, Besançon, France; EFS Bourgogne Franche-Comté, Plateforme de Biomonitoring, INSERM CIC1431, Besançon, France
| | - Anne Dormoy
- EFS Bourgogne Franche-Comté, Plateforme de Biomonitoring, INSERM CIC1431 , Besançon, France
| | - François Aubin
- Department of Dermatology, University Hospital of Besançon, EA3181, SFR4234 , Besançon cedex, France
| | - Pascale Jacoulet
- Department of Pneumology, University Hospital of Besançon , Besançon cedex, France
| | - Virginie Westeel
- Department of Pneumology, University Hospital of Besançon , Besançon cedex, France
| | - Christophe Borg
- INSERM, UMR1098, LabEx LipSTIC, Besançon, France; EFS Bourgogne Franche-Comté, Plateforme de Biomonitoring, INSERM CIC1431, Besançon, France; Univ. Bourgogne Franche-Comté, UMR1098, Besançon, France; Department of Medical Oncology, University Hospital of Besançon, Besançon cedex, France
| | - Eric Tartour
- INSERM, UMR970, Hôpital Européen Georges Pompidou, Paris, France, Department of Biological Immunology, Assistance Publique-Hôpitaux de Paris, Hôpital Européen Georges Pompidou, Paris, France, University Paris Descartes , Sorbonne Paris Cité , Paris, France
| | - Yann Godet
- INSERM, UMR1098, LabEx LipSTIC, Besançon, France; Univ. Bourgogne Franche-Comté, UMR1098, Besançon, France
| | - Bernard Maillère
- CEA, iBiTecS, Service d'Ingénierie Moléculaire des Protéines (SIMOPRO), Labex LERMIT, Labex VRI , Gif Sur Yvette, France
| | - Olivier Adotévi
- INSERM, UMR1098, LabEx LipSTIC, Besançon, France; Univ. Bourgogne Franche-Comté, UMR1098, Besançon, France; Department of Medical Oncology, University Hospital of Besançon, Besançon cedex, France
| |
Collapse
|
39
|
Wu T, Leboeuf C, Durand S, Su B, Deschamps M, Zhang X, Ferrand C, Pessaux P, Robinet E. Suicide gene-modified killer cells as an allogeneic alternative to autologous cytokine-induced killer cell immunotherapy of hepatocellular carcinoma. Mol Med Rep 2016; 13:2645-54. [PMID: 26820174 DOI: 10.3892/mmr.2016.4811] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/21/2015] [Accepted: 12/15/2015] [Indexed: 11/06/2022] Open
Abstract
Adoptive immunotherapy using autologous cytokine-induced killer (CIK) cells reduces the recurrence rate of hepatocellular carcinoma (HCC) in association with transarterial chemoembolization or radiofrequency. However, a large‑scale development of this immunotherapy remains difficult to consider in an autologous setting, considering the logistical hurdles associated with the production of this cell therapy product. A previous study has provided the in vitro and in vivo proof‑of‑concept that allogeneic suicide gene‑modified killer cells (aSGMKCs) from healthy blood donors (a cell therapy product previously demonstrated to provide anti‑leukemic effects to patients receiving allogeneic hematopoietic transplantation) may exert a potent anti‑tumor effect towards HCC. Therefore, the development of a bank of 'ready‑for‑use' aSGMKCs was proposed as an approach allowing for the development of immunotherapies that are more convenient and on a broader scale than that of autologous therapies. In the present study, aSGMKCs were compared with CIK cells generated according to three different protocols. Similar to CIK cells, the cytotoxic activity of aSGMKCs toward the Huh‑7 HCC cell line was mediated by tumor necrosis factor‑related apoptosis‑inducing ligand, tumor necrosis factor‑α and interferon‑γ. Furthermore, the frequency of natural killer (NK), NK‑like T and T cells, and their in vitro and in vivo cytotoxicity activities were similar between aSGMKCs and CIK cells. Thus, the present study demonstrated that aSGMKCs are similar to CIK cells, further suggesting the possibility for future use of aSGMKCs in the treatment of solid tumors, including HCC.
Collapse
Affiliation(s)
- Tao Wu
- Department of Hepatobiliary and Pancreatic Surgery, Second Affiliated Hospital of Kunming Medical University, Kunming, Yunnan 650500, P.R. China
| | - Céline Leboeuf
- French National Institute of Health and Medical Research, Research Unit 1110, F-67000 Strasbourg, France
| | - Sarah Durand
- French National Institute of Health and Medical Research, Research Unit 1110, F-67000 Strasbourg, France
| | - Bin Su
- French National Institute of Health and Medical Research, Research Unit 1110, F-67000 Strasbourg, France
| | - Marina Deschamps
- French National Blood Service (Bourgogne/Franche‑Comté), Research Unit 1098, F-25000 Besançon, France
| | - Xiaowen Zhang
- Department of Hepatobiliary and Pancreatic Surgery, Second Affiliated Hospital of Kunming Medical University, Kunming, Yunnan 650500, P.R. China
| | - Christophe Ferrand
- French National Blood Service (Bourgogne/Franche‑Comté), Research Unit 1098, F-25000 Besançon, France
| | - Patrick Pessaux
- French National Institute of Health and Medical Research, Research Unit 1110, F-67000 Strasbourg, France
| | - Eric Robinet
- French National Institute of Health and Medical Research, Research Unit 1110, F-67000 Strasbourg, France
| |
Collapse
|
40
|
Macquet AC, Ferrand C, Stanton NA. Divide and rule: A qualitative analysis of the debriefing process in elite team sports. Appl Ergon 2015; 51:30-38. [PMID: 26154201 DOI: 10.1016/j.apergo.2015.04.005] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/16/2015] [Revised: 04/09/2015] [Accepted: 04/14/2015] [Indexed: 06/04/2023]
Abstract
This article aimed to gain an understanding of the process of debriefing during major competitions in elite team sports. Debrief interviews were conducted with 9 head coaches. The interview data were used to identify how head coaches divided up the tasks given to staff and team members prior to, and during the post-match debriefing. Results showed that debriefing consisted of two steps: preparation and presentation. Preparation referred to four successive tasks. Presentation to the team of players consisted of eight tasks relating to transformational and transactional styles of leadership. Coaches were shown to divide the labor within the staff and team. The data tend to support the view that in elite team sports, coaches are both transformational and transactional leaders, adapting their style of leadership to the situation, athletes and time available. This study provides insights into the task-work and team-work underlying team functioning and division of labor.
Collapse
Affiliation(s)
- A-C Macquet
- National Institute of Sports, Expertise and Performance (INSEP), Paris, France.
| | - C Ferrand
- Université François Rabelais, Tours, France
| | | |
Collapse
|
41
|
Bole-Richard E, Deschamps M, Ferrand C, Robinet E. Editorial: Improving the safety of cell therapy products by suicide gene transfer. Front Pharmacol 2015; 6:174. [PMID: 26379549 PMCID: PMC4548201 DOI: 10.3389/fphar.2015.00174] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/29/2015] [Accepted: 08/03/2015] [Indexed: 12/03/2022] Open
Affiliation(s)
- Elodie Bole-Richard
- Institut National de la Santé et de la Recherche Médicale UMR 1098, Etablissement Français du Sang Bourgogne/Franche-Comté Besançon, France ; SFR FRD 4234 Ingénierie et Biologie Cellulaire et Tissulaire, Université de Franche-Comté Besançon, France
| | - Marina Deschamps
- Institut National de la Santé et de la Recherche Médicale UMR 1098, Etablissement Français du Sang Bourgogne/Franche-Comté Besançon, France ; SFR FRD 4234 Ingénierie et Biologie Cellulaire et Tissulaire, Université de Franche-Comté Besançon, France
| | - Christophe Ferrand
- Institut National de la Santé et de la Recherche Médicale UMR 1098, Etablissement Français du Sang Bourgogne/Franche-Comté Besançon, France ; SFR FRD 4234 Ingénierie et Biologie Cellulaire et Tissulaire, Université de Franche-Comté Besançon, France
| | - Eric Robinet
- Institut National de la Santé et de la Recherche Médicale UMR 1110, Institut de Recherche sur les Maladies Virales et Hépatiques Strasbourg, France ; Institut Hospitalo-Universitaire de Strasbourg Strasbourg, France
| |
Collapse
|
42
|
Gamonet C, Deschamps M, Marion S, Herbein G, Chiocchia G, Auger I, Saas P, Ferrand C, Toussirot E. The alternative CD20 transcript variant is not a surrogate marker for resistance to rituximab in patients with rheumatoid arthritis: Fig. 1. Rheumatology (Oxford) 2015; 54:1744-5. [DOI: 10.1093/rheumatology/kev210] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
43
|
Bole-Richard E, Certoux JM, Pallandre JR, Idirene I, Borg C, Ferrand C, Deschamps M. CAR-T cell immunotherapies targeting type III variant epidermal growth factor receptor, a glioma-associated antigen. J Clin Oncol 2015. [DOI: 10.1200/jco.2015.33.15_suppl.e14022] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
| | | | | | | | - Christophe Borg
- EFS B-FC - Centre Hospitalo-Universitaire de Besançon, Besancon, France
| | | | | |
Collapse
|
44
|
Etienne-Grimaldi MC, Boyer JC, Llorca L, Romieu G, Bachelot TD, Dieras V, Merlin JL, Pinguet F, Thomas F, Ferrand C, Bobin-Dubigeon C, Pivot XB, Largillier R, Mousseau M, Goncalves A, Roche HH, Ciccolini J, Ferrero JM, Milano GA. Exhaustive single nucleotide polymorphism (SNP) analysis of DPYD exome in breast cancer patients (pts) receiving capecitabine. J Clin Oncol 2015. [DOI: 10.1200/jco.2015.33.15_suppl.2571] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
| | | | | | | | | | | | - Jean-Louis Merlin
- Institut de Cancérologie de Lorraine, Service de Biopathologie, CNRS UMR 7039 CRAN Université de Lorraine, Nancy, France
| | | | | | | | | | | | | | | | | | | | - Joseph Ciccolini
- Transfert Oncology Laboratory, Nord University Hospital of Marseille, Marseille, France
| | - Jean-Marc Ferrero
- Department d'Oncologie Medicale, Centre Antoine Lacassagne, Nice, France
| | | | | |
Collapse
|
45
|
Crepin T, Carron C, Roubiou C, Gaugler B, Gaiffe E, Simula-Faivre D, Ferrand C, Tiberghien P, Chalopin JM, Moulin B, Frimat L, Rieu P, Saas P, Ducloux D, Bamoulid J. ATG-induced accelerated immune senescence: clinical implications in renal transplant recipients. Am J Transplant 2015; 15:1028-38. [PMID: 25758660 DOI: 10.1111/ajt.13092] [Citation(s) in RCA: 70] [Impact Index Per Article: 7.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/05/2014] [Revised: 10/16/2014] [Accepted: 11/01/2014] [Indexed: 01/25/2023]
Abstract
Persistent ATG-induced CD4(+) T cell lymphopenia is associated with serious clinical complications. We tested the hypothesis that ATG induces accelerated immune senescence in renal transplant recipients (RTR). Immune senescence biomarkers were analyzed at transplant and one-year later in 97 incident RTR -62 patients receiving ATG and 35 receiving anti-CD25 mAb (α-CD25). This consisted in: (i) thymic output; (ii) bone marrow renewal of CD34(+) hematopoietic progenitor cells (CD34(+) HPC) and lymphoid (l-HPC) and myeloid (m-HPC) progenitor ratio; (iii) T cell phenotype; and (iv) measurement of T cell relative telomere length (RTL) and telomerase activity (RTA). Clinical correlates were analyzed with a 3 year follow-up. Thymic output significantly decreased one-year posttransplant in ATG-treated patients. ATG was associated with a significant decrease in l-HPC/m-HPC ratio. Late stage differentiated CD57(+) /CD28(-) T cells increased in ATG-treated patients. One-year posttransplant T cell RTL and RTA were consequently lower in ATG-treated patients. ATG is associated with accelerated immune senescence. Increased frequency of late differentiated CD4(+) T cell frequency at transplantation tended to be predictive of a higher risk of subsequent opportunistic infections and of acute rejection only in ATG-treated patients but this needs confirmation. Considering pretransplant immune profile may help to select those patients who may benefit from ATG to prevent severe infections and acute rejection.
Collapse
Affiliation(s)
- T Crepin
- INSERM, UMR1098, Federation Hospitalo-Universitaire INCREASE, Besançon, France; Université de Franche-Comté, Faculté de Médecine et de Pharmacie, Besançon, France; Structure Fédérative de Recherche, SFR FED4234, Besançon, France; CHU Besançon, Department of Nephrology, Dialysis, and Renal Transplantation, Besançon, France
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
46
|
Gamonet C, Bole-Richard E, Delherme A, Aubin F, Toussirot E, Garnache-Ottou F, Godet Y, Ysebaert L, Tournilhac O, Dartigeas C, Larosa F, Deconinck E, Saas P, Borg C, Deschamps M, Ferrand C. Erratum to: New CD20 alternative splice variants: molecular identification and differential expression within hematological B cell malignancies. Exp Hematol Oncol 2015; 5:10. [PMID: 27081577 PMCID: PMC4831155 DOI: 10.1186/s40164-016-0038-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/30/2016] [Accepted: 03/30/2016] [Indexed: 12/03/2022] Open
Affiliation(s)
- Clémentine Gamonet
- INSERM UMR1098, Établissement Français du Sang Bourgogne Franche Comté, Université de Franche-Comté, SFR FED4234, 25020 Besançon, France
| | - Elodie Bole-Richard
- INSERM UMR1098, Établissement Français du Sang Bourgogne Franche Comté, Université de Franche-Comté, SFR FED4234, 25020 Besançon, France
| | - Aurélia Delherme
- INSERM UMR1098, Établissement Français du Sang Bourgogne Franche Comté, Université de Franche-Comté, SFR FED4234, 25020 Besançon, France
| | - François Aubin
- EA3181 et Service de Dermatologie, Université de Franche Comté, CHU de Besançon, Besançon, France
| | - Eric Toussirot
- EA3181 et Service de Dermatologie, Université de Franche Comté, CHU de Besançon, Besançon, France ; CHRU, Department of Rheumatology, Université de Franche-Comté EA 4266, INSERM CIC-1431, 25000 Besançon, France ; EA 4266, Université de Franche-Comté, Besançon, France
| | - Francine Garnache-Ottou
- INSERM UMR1098, Établissement Français du Sang Bourgogne Franche Comté, Université de Franche-Comté, SFR FED4234, 25020 Besançon, France ; EA3181 et Service de Dermatologie, Université de Franche Comté, CHU de Besançon, Besançon, France
| | - Yann Godet
- INSERM UMR1098, Établissement Français du Sang Bourgogne Franche Comté, Université de Franche-Comté, SFR FED4234, 25020 Besançon, France ; EA3181 et Service de Dermatologie, Université de Franche Comté, CHU de Besançon, Besançon, France
| | - Loïc Ysebaert
- Inserm U1037, Université Toulouse 3-ERL CNRS, CHU Purpan, Toulouse, France
| | - Olivier Tournilhac
- Hématologie Clinique, CHU Estaing, 1 Place Lucie Aubrac, 63003 Clermont-Ferrand Cedex 1, France
| | | | - Fabrice Larosa
- INSERM UMR1098, Établissement Français du Sang Bourgogne Franche Comté, Université de Franche-Comté, SFR FED4234, 25020 Besançon, France ; Hematology Department, CHU Jean Minjoz, 25020 Besançon, France
| | - Eric Deconinck
- INSERM UMR1098, Établissement Français du Sang Bourgogne Franche Comté, Université de Franche-Comté, SFR FED4234, 25020 Besançon, France ; EA3181 et Service de Dermatologie, Université de Franche Comté, CHU de Besançon, Besançon, France ; Hematology Department, CHU Jean Minjoz, 25020 Besançon, France
| | - Philippe Saas
- INSERM UMR1098, Établissement Français du Sang Bourgogne Franche Comté, Université de Franche-Comté, SFR FED4234, 25020 Besançon, France ; EA3181 et Service de Dermatologie, Université de Franche Comté, CHU de Besançon, Besançon, France
| | - Christophe Borg
- INSERM UMR1098, Établissement Français du Sang Bourgogne Franche Comté, Université de Franche-Comté, SFR FED4234, 25020 Besançon, France ; EA3181 et Service de Dermatologie, Université de Franche Comté, CHU de Besançon, Besançon, France
| | - Marina Deschamps
- INSERM UMR1098, Établissement Français du Sang Bourgogne Franche Comté, Université de Franche-Comté, SFR FED4234, 25020 Besançon, France
| | - Christophe Ferrand
- INSERM UMR1098, Établissement Français du Sang Bourgogne Franche Comté, Université de Franche-Comté, SFR FED4234, 25020 Besançon, France ; Laboratoire de Thérapeutique Immuno-Moléculaire et cellulaire des cancers, INSERM UMR1098, Etablissement Français du Sang-Bourgogne/Franche-Comté, 8, rue du Docteur Jean-François-Xavier Girod, 25020 Besançon Cedex, France
| |
Collapse
|
47
|
Vauchy C, Gamonet C, Ferrand C, Daguindau E, Galaine J, Beziaud L, Chauchet A, Henry Dunand CJ, Deschamps M, Rohrlich PS, Borg C, Adotevi O, Godet Y. CD20 alternative splicing isoform generates immunogenic CD4 helper T epitopes. Int J Cancer 2014; 137:116-26. [DOI: 10.1002/ijc.29366] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/22/2014] [Revised: 11/12/2014] [Accepted: 11/18/2014] [Indexed: 12/22/2022]
Affiliation(s)
- Charline Vauchy
- INSERM UMR1098, F25020 Besançon cedex; France
- Université de Franche-Comté, F25020 Besançon cedex; France
- EFS Bourgogne Franche-Comté, F25020 Besançon cedex; France
| | - Clementine Gamonet
- INSERM UMR1098, F25020 Besançon cedex; France
- Université de Franche-Comté, F25020 Besançon cedex; France
- EFS Bourgogne Franche-Comté, F25020 Besançon cedex; France
| | - Christophe Ferrand
- INSERM UMR1098, F25020 Besançon cedex; France
- Université de Franche-Comté, F25020 Besançon cedex; France
- EFS Bourgogne Franche-Comté, F25020 Besançon cedex; France
| | - Etienne Daguindau
- Department of Hematology; University Hospital of Besançon, F25020 Besançon cedex; France
| | - Jeanne Galaine
- INSERM UMR1098, F25020 Besançon cedex; France
- Université de Franche-Comté, F25020 Besançon cedex; France
- EFS Bourgogne Franche-Comté, F25020 Besançon cedex; France
| | - Laurent Beziaud
- INSERM UMR1098, F25020 Besançon cedex; France
- Université de Franche-Comté, F25020 Besançon cedex; France
- EFS Bourgogne Franche-Comté, F25020 Besançon cedex; France
| | - Adrien Chauchet
- Department of Hematology; University Hospital of Besançon, F25020 Besançon cedex; France
| | - Carole J. Henry Dunand
- The Department of Medicine; Section of Rheumatology, The Knapp Center for Lupus and Immunology Research, The University of Chicago; Chicago IL
| | - Marina Deschamps
- INSERM UMR1098, F25020 Besançon cedex; France
- Université de Franche-Comté, F25020 Besançon cedex; France
- EFS Bourgogne Franche-Comté, F25020 Besançon cedex; France
| | - Pierre Simon Rohrlich
- INSERM UMR1098, F25020 Besançon cedex; France
- Université de Franche-Comté, F25020 Besançon cedex; France
- Department of Pediatrics; University Hospital of Besançon, F25020 Besançon cedex; France
| | - Christophe Borg
- INSERM UMR1098, F25020 Besançon cedex; France
- Université de Franche-Comté, F25020 Besançon cedex; France
- EFS Bourgogne Franche-Comté, F25020 Besançon cedex; France
- Department of Medical Oncology; University Hospital of Besançon, F25020 Besançon cedex; France
| | - Olivier Adotevi
- INSERM UMR1098, F25020 Besançon cedex; France
- Université de Franche-Comté, F25020 Besançon cedex; France
- EFS Bourgogne Franche-Comté, F25020 Besançon cedex; France
- Department of Medical Oncology; University Hospital of Besançon, F25020 Besançon cedex; France
| | - Yann Godet
- INSERM UMR1098, F25020 Besançon cedex; France
- Université de Franche-Comté, F25020 Besançon cedex; France
- EFS Bourgogne Franche-Comté, F25020 Besançon cedex; France
| |
Collapse
|
48
|
Guenat D, Quentin S, Rizzari C, Lundin C, Coliva T, Edery P, Fryssira H, Bermont L, Ferrand C, Soulier J, Borg C, Rohrlich PS. Constitutional and somatic deletions of the Williams-Beuren syndrome critical region in non-Hodgkin lymphoma. J Hematol Oncol 2014; 7:82. [PMID: 25388916 PMCID: PMC4228180 DOI: 10.1186/s13045-014-0082-4] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/25/2014] [Accepted: 10/20/2014] [Indexed: 01/28/2023] Open
Abstract
Here, we report and investigate the genomic alterations of two novel cases of Non-Hodgkin Lymphoma (NHL) in children with Williams-Beuren syndrome (WBS), a multisystem disorder caused by 7q11.23 hemizygous deletion. Additionally, we report the case of a child with NHL and a somatic 7q11.23 deletion. Although the WBS critical region has not yet been identified as a susceptibility locus in NHL, it harbors a number of genes involved in DNA repair. The high proportion of pediatric NHL reported in WBS is intriguing. Therefore, the role of haploinsufficiency of genes located at 7q11.23 in lymphomagenesis deserves to be investigated.
Collapse
Affiliation(s)
- David Guenat
- Laboratory of Cellular and Molecular Biology, University Hospital of Besançon, 1 Bd Fleming, Batiment Diaclone, Besançon, France.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
49
|
Zver T, Alvergnas-Vieille M, Garnache-Ottou F, Ferrand C, Roux C, Amiot C. Minimal residual disease detection in cryopreserved ovarian tissue by multicolor flow cytometry in acute myeloid leukemia. Haematologica 2014; 99:e249-52. [PMID: 25239266 DOI: 10.3324/haematol.2014.113373] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022] Open
Affiliation(s)
- Tristan Zver
- Service de Génétique Biologique, Histologie, Biologie du Développement et de la Reproduction, CHRU Jean Minjoz; INSERM UMR1098; Université de Franche-Comté, SFR FED4234
| | - Magalie Alvergnas-Vieille
- Service de Génétique Biologique, Histologie, Biologie du Développement et de la Reproduction, CHRU Jean Minjoz; INSERM CIC-1431, CHRU Jean Minjoz; and
| | - Francine Garnache-Ottou
- INSERM UMR1098; Université de Franche-Comté, SFR FED4234; INSERM CIC-1431, CHRU Jean Minjoz; and EFS Bourgogne Franche-Comté, Besançon, France
| | | | - Christophe Roux
- Service de Génétique Biologique, Histologie, Biologie du Développement et de la Reproduction, CHRU Jean Minjoz; INSERM UMR1098; Université de Franche-Comté, SFR FED4234; INSERM CIC-1431, CHRU Jean Minjoz; and
| | - Clotilde Amiot
- Service de Génétique Biologique, Histologie, Biologie du Développement et de la Reproduction, CHRU Jean Minjoz; INSERM UMR1098; Université de Franche-Comté, SFR FED4234; INSERM CIC-1431, CHRU Jean Minjoz; and
| |
Collapse
|
50
|
Mansi L, Daguindau E, Saas P, Pouthier F, Ferrand C, Dormoy A, Patry I, Garnache F, Rohrlich PS, Deconinck E, Larosa F. Diagnosis and management of nocardiosis after bone marrow stem cell transplantation in adults: Lack of lymphocyte recovery as a major contributing factor. ACTA ACUST UNITED AC 2014; 62:156-61. [DOI: 10.1016/j.patbio.2014.04.001] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/07/2013] [Accepted: 04/24/2014] [Indexed: 10/25/2022]
|